Protocol Number: VXA -NVV -202 
 
Official Title:  A Phase 2, Multicenter, Randomized, Double -blind, Placebo -controlled, Single Dose, 
Dose-ranging Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 
Vaccine Administered Orally to Healthy Volunteers Aged ≥ 18 Years and ≤ 80 Years Old 
 
Study ID: [REMOVED]  
 
Document Date: 22 February  2023 
Vaxart Inc  
VXA -NVV -202 Version 2 .0  09 Feb 2023  
 
Clinical Study Protocol 
Protocol Title:  A phase 2, multicenter, randomized, double -blind, placebo -controlled, 
single dose, dose -ranging study to determine the safety and immunogenicity 
of bivalent GI.1 and GII.4 vaccine administered orally to healthy volunteers 
aged ≥ 18 years and ≤ 80 years  old. 
Protocol Number:  VXA -NVV -202 
IND Numbers:  BB-IND 16796  
Product Names: 
 Bivalent GI.1 and GII.4 vaccines (VXA -G1.1 -NN plus VXA GII.4 -NS) 
Indication:  Prevention of No rovirus I nfection  
Sponsor 
 Vaxart, Inc.  
170 Harbor Way, Suite 300  
South San Francisco, CA 94080  
  
Sponsor Contact  
  
 
Ph: ; Email:  
  
 
Medical Monitor  
  
 
Ph:  Email:  
 
 
 
Ph: ;  
Email:  
Protocol Version  and 
Version Date 
 2.0  09 Feb 2023 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0  09 Feb 2023  
 
Prior Version   
1.0 13- Oct-2022 
Protocol Title: A phase 2, multicenter, randomized, double -blind, placebo -controlled, single dose, dose -
ranging study to determine the safety and immunogenicity of bivalent GI.1 and GII.4 vaccine administered 
orally to healthy volunteers ≥ 18 years and ≤ 80 years old . 
 
Protocol Number: VXA -NVV -202 
 
Amendment Number: 2.0 
 
Date of Amendment  (Optional): .09 Feb 2023  
 
IND Number : BB-IND 16796 
 
Investigational Product Name : Bivalent GI.1 and GII.4 vaccines (VXA-G1.1- NN plus 
VXA -GII.4 -NS) 
 
 
Phase:    II 
 
Sponsor:    Vaxart, Inc.  
      170 Harbor Way, Suite 300  
       South San Francisco, CA 94080  
 
Funding Sponsor:  Vaxart, Inc.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
____________________________________________________________________________________________ 
Confidentiality Statement  
This document is confidential and is to be distributed for review only to Investigators, potential Investigators, 
consultants, study staf f, and applicable independent ethics committees or institutional review boards. The contents of 
this document shall not be disclosed to others without written permission from Sponsor (or others, as applicable). 
_____________________________________________ ________________________________________________    
DocuSign Envelope ID: 

Vaxart I
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL                                                                                                                                                                   Page 3 of 106 
 SIGNATURE  
 
PROTOCOL TITLE : A phase 2, multicenter, randomized, double -blind, placebo -controlled, 
single dose, dose -ranging study to determine the safety and immunogenicity of bivalent GI.1 and 
GII.4 vaccine administered orally to healthy volunteers ≥ 18 years and ≤ 80 years old.  
PROTOCOL NUMBER : VXA -NVV -202 
PROTOCOL VERSION (Amendment): Not applicable  
 
Signature of Sponsor’s authorized representative(s):  
 
                   ________________ 
       Date  
                                                                                    
 
 
 
 
 
 
 
 
 
 
  
 
DocuSign Envelope ID: 
2/22/2023

Vaxart I
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL                                                                                                                                                                   Page 4 of 106 
 STATEMENT OF COMPLIANCE  
This trial will be conducted in accordance with International Conference on Harmonisation Good 
Clinical Practice (ICH GCP), the ethical principles that have their origin in the Declaration of 
Helsinki and the Code of Federal Regulations on the Protection of Human Participant s (45 CFR 
Part 46). The Principal Investigator will assure that no deviation from, or changes to the protocol 
will take place without prior agreement from the Sponsor, funding agency  and documented 
approval from the Institutional Review Board (IRB), except where necessary to eliminate an 
immediate hazard(s) to the trial Subject s. All personnel involved in the conduct of this study have 
completed Human Subject s Protection and ICH GCP Training  per country requirements. 
 
I agree to ensure that all staff members involved in the conduct of this trial are informed about 
their obligations in meeting the above commitments. 
 
 
 
Principal Investigator: ___________________                                        ___________________ 
                                   Signature                                                                   Date  
 
 
Name:             __________________________ 
 
 
Address:         ___________________________ 
 
                                                       
                            ______________________________                                                                                                             
 
 
                             ______________________________  
                            (Full Address, Landmark, State, Country, Phone: Fax:)    
DocuSign Envelope ID: 

Vaxart I
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL                                                                                                                                                                   Page 5 of 106 
 TABLE  OF CONTENTS  
SIGNATURE  .......................................................................................................................  3 
STATEMENT OF COMPLIANCE  ........................................................................................  4 
TABLE OF CONTENTS  ......................................................................................................  5 
LIST OF IN -TEXT TABLE  ..................................................................................................  8 
LIST OF IN -TEXT FIGURE  ................................................................................................  8 
LIST OF ABBREVIATIONS [AND DEFINITIONS OF TERMS]  ............................................  9 
1. Protocol synopsis  ......................................................................................................  11 
1.1 Schedule of Trial Activities  .........................................................................................................................  21 
2. Introduction  ............................................................................................................. 24 
2.1 Indication  .....................................................................................................................................................  24 
2.2 Background  ..................................................................................................................................................  24 
2.2.1 Background of disease  .........................................................................................................................  24 
2.2.2 Non-clinical experience with Bivalent GI.1 and GII.4 vaccine  .........................................................  24 
2.2.3 Clinical experience with Bivalent GI.1 and GII.4 vaccine  ................................................................  25 
2.3 Trial Rationale  .............................................................................................................................................  26 
2.4 Risk / Benefit Assessment  ...........................................................................................................................  26 
2.4.1 Known Potential Risks to the Subjects  ...............................................................................................  26 
2.4.2 Known Potential Benefits to the subject  .............................................................................................  27 
2.4.3 Overall Benefit Risk Conclusion  .........................................................................................................  27 
3. Trial Objective and end points  .................................................................................. 27 
3.1 Objectives  .....................................................................................................................................................  27 
3.1.1 Primary Objectives   ..........................................................................................................................  27 
3.2 End Points  ....................................................................................................................................................  27 
3.2.1 Primary End Points   ..........................................................................................................................  27 
3.2.2 Exploratory End Points  .......................................................................................................................  28 
4. Trial Design  .............................................................................................................. 29 
4.1 Overall Description of Trial Design  ...........................................................................................................  29 
4.2 Scientific Rationale of Trial Design  ...........................................................................................................  32 
4.3 Justification for dose selection  ....................................................................................................................  32 
4.4 End of the study definition  .........................................................................................................................  33 
4.5 Premature Termination or Suspension of Trial  .......................................................................................  33 
4.6 Trial and Site Start and Close -Out ............................................................................................................  34 
4.6.1 First Act of Recruitment  ......................................................................................................................  34 
4.6.2 Study/Site Termination  ........................................................................................................................  34 
5. Selection of Trial Population  ..................................................................................... 34 
5.1 Inclusion Criteria  ........................................................................................................................................  34 
5.2 Early Termination/ Withdrawal criteria  ...................................................................................................  38 
5.3 Lost to follow up Procedure  .......................................................................................................................  39 
5.4 Screening Failure  .........................................................................................................................................  39 
5.5 Classification of Subjects Who Discontinue the Study  .............................................................................  39 
6. Trial Intervention  ..................................................................................................... 41 
6.1 Investigational Product Description  ..........................................................................................................  41 
6.2 Preparation and Dispensing of Investigational Product  ..........................................................................  42 
DocuSign Envelope ID: 

Vaxart I
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL                                                                                                                                                                   Page 6 of 106 
 6.3 Dosing and Administration of Investigational Product  ...........................................................................  42 
6.4 Formulation,  Appearance, Packaging , and Labelling  ..............................................................................  43 
6.5 Product Storage and Stability  ....................................................................................................................  43 
6.6 Accountability Procedures  ..........................................................................................................................  44 
6.7 Randomization and Blinding  ......................................................................................................................  44 
6.7.1 Randomization Procedures  .................................................................................................................  44 
6.7.2 Blinding Procedures   ..........................................................................................................................  45 
6.8 Treatment Compliance  ...............................................................................................................................  46 
6.9 Overdose of Treatment  ...............................................................................................................................  46 
6.10 Concomitant Medications and Other Therapies  ......................................................................................  46 
7. Schedule of Trial Procedures and Assessments  ........................................................... 47 
7.1 Trial Procedures  ..........................................................................................................................................  47 
7.1.1 Procedure to be followed on screening Day -45 to Day -1) ...............................................................  47 
7.1.2 Procedure to be followed during Active Study Period (Day 1 to Day 29)  .......................................  48 
7.1.3 Procedure to be followed during follow -up period (Day 30 to Day 365)  .........................................  49 
7.1.4 Unscheduled Visit   ..........................................................................................................................  50 
7.2 Management of Blood / Saliva / Nasal Samples  ........................................................................................  51 
7.2.1 Blood / Saliva/Nasal Sample Collection  .....................................................................................................  51 
7.2.2 Blood/ Saliva/Nasal  Sample Preparation  ...................................................................................................  51 
7.2.3 Blood/ Saliva/Nasal  Sample Storage and Shipment  .................................................................................  51 
7.2.4 Future use of stored specimens and data  ...................................................................................................  51 
8. Trial Assessments and Procedures  ............................................................................. 52 
8.1 Safety Assessment  ........................................................................................................................................  52 
8.1.1 Physical Examination   ..........................................................................................................................  53 
8.1.2 Vital Signs   ..........................................................................................................................  53 
8.1.3 Clinical Safety Laboratory Tests  ........................................................................................................  53 
8.1.4 Pregnancy Testing   ..........................................................................................................................  53 
8.2 Immunogenicity Assessments  .....................................................................................................................  53 
9. Adverse Events  ......................................................................................................... 55 
9.1.1 Definition of an Adverse Event, Serious Adverse Event, Adverse Event of Special Interest, New 
Onset of Chronic Illness, and Unanticipated problems  ..................................................................................  55 
9.1.2 Grading of Severity of an Adverse Event  ...........................................................................................  57 
9.1.3 Relationship of Adverse Event Following Immunization to Experimental Vaccine /Vaccine 
Adverse Event Causality Assessment  ...............................................................................................................  58 
9.1.4 Monitoring of Adverse Events during Trial  ......................................................................................  59 
9.1.4.1   Monitoring of AE/SAEs from Day 1 to Day 29 after vaccination  ........................................................  59 
9.1.5 Time Period and Frequency for Collecting AE, AESI, NOCIs, and SAE Information  .................  59 
9.1.6 Follow-up of AEs, AESIs, NOCIs and SAEs  ......................................................................................  60 
9.1.7 Reporting of Adverse Event, Adverse Event of Special Interest, New Onset of Chronic Illness, 
Serious Adverse Events and Unanticipated problems  ....................................................................................  60 
9.1.8 Pregnancy   ..........................................................................................................................  62 
10. Safety Oversight  ....................................................................................................... 63 
10.1 Internal Sponsor Review  .............................................................................................................................  63 
10.2 Safety Monitoring Committee  ....................................................................................................................  64 
11. Statistical Consideration  ........................................................................................... 65 
11.1 Hypothesis  ....................................................................................................................................................  65 
11.2 Sample Size Determination  .........................................................................................................................  65 
DocuSign Envelope ID: 

Vaxart I
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL                                                                                                                                                                   Page 7 of 106 
 11.3 Multiplicity Adjustment  ..............................................................................................................................  65 
11.4 Population for Analysis  ...............................................................................................................................  65 
11.5 Statistical Analysis Plan  ..............................................................................................................................  66 
11.5.1 General Approach   ..........................................................................................................................  66 
11.5.2 Analysis of the Primary Safety End Points  ........................................................................................  66 
11.5.3 Analysis of Primary and Exploratory Immunogenicity End Points  ................................................  67 
11.5.4 Baseline descriptive Statistics  ..............................................................................................................  68 
11.5.5 Sub-group Analysis   ..........................................................................................................................  68 
11.5.6 Tabulation of Individual Subject Data  ...............................................................................................  68 
12. Ethical Consideration  ............................................................................................... 69 
12.1 Ethical Conduct of the Study  .....................................................................................................................  69 
12.2 Institutional Review Board  .........................................................................................................................  69 
12.3 Inform Consent Process  ..............................................................................................................................  69 
12.4 Insurance Compensation  ............................................................................................................................  70 
12.5 Stipends/Rewards/Compensation for Participation  .................................................................................  70 
12.6 Subject Confidentiality  ...............................................................................................................................  70 
12.7 Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP  .....................................  71 
13. Data Handling and Record Keeping  .......................................................................... 71 
13.1 Source Documents  .......................................................................................................................................  71 
13.2 Case Report Forms (CRF)  ..........................................................................................................................  72 
13.3 Data Collection and Management Responsibility  .....................................................................................  72 
13.4 Record Retention  .........................................................................................................................................  73 
13.5 Property Rights and Data Protection  ........................................................................................................  73 
14. Quality Control and Quality Assurance  ..................................................................... 74 
14.1 Early Safety Data Review AND/OR Committee  .......................................................................................  74 
14.2 Clinical Trial Site Monitoring  ....................................................................................................................  74 
14.3 Audit and Inspection  ...................................................................................................................................  75 
14.4 Responsibility of Investigator  .....................................................................................................................  75 
14.5 Responsibility of Sponsor  ...........................................................................................................................  76 
14.6 Protocol Deviation  .......................................................................................................................................  76 
15. Publication and Data Sharing Policy  ......................................................................... 77 
16. References  ................................................................................................................ 78 
Appendix 1: Clinical Laboratory Tests  ................................................................................ 79 
Appendix 2: Country -specific Requirements  ....................................................................... 79 
Appendix 3: Adverse Events Grading  .................................................................................. 79 
Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information  ................... 81 
Definitions   ..........................................................................................................................  81 
Contraception Guidance   ..........................................................................................................................  81 
Collection of Pregnancy Information  ...............................................................................................................  81 
Appendix 5: Adverse Events of Special Interest  ................................................................... 82 
Appendix 6.0 Prot ocol Version History  ............................................................................... 84 
VERSION 1.0  .........................................................................................................................................................  84 
12 OCT 2022  ...........................................................................................................................................................  84 
INITIAL VERSION ...............................................................................................................................................  84 
VERSION 2.0 `  .......................................................................................................................................................  84 
DocuSign Envelope ID: 

Vaxart I
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL                                                                                                                                                                   Page 8 of 106 
 09 FEB 2023  ...........................................................................................................................................................  84 
AMENDMENT 1.0  ................................................................................................................................................  84 
 
LIST OF IN -TEXT TABLE  
Table 1: Schedule of Activities  .......................................................................................................................  21 
Table 2:  Sentinel Subjects  ..............................................................................................................................  30 
Table 3: Study Design  .....................................................................................................................................  30 
Table 4: Study Duration  ................................................................................................................................ . 32 
Table 5: Discontinuation Reasons  .................................................................................................................  40 
Table 6:  Investigational Product Dosing  .......................................................................................................  42 
Table 7: Study Arm(s)  ....................................................................................................................................  43 
Table 8: Adverse Event Reporting Timelines to the Sponsor  .....................................................................  61 
Table 9: Populations for Analyses  .................................................................................................................  65 
Table 10 Protocol-Required Laboratory Assessments  .................................................................................  79 
Table 11 Grading of Solicited Symptoms of Reactogenicity  ........................................................................  80 
Table 12:  Adverse Events of Special Interest  ................................................................................................ . 82 
 
LIST OF IN -TEXT FIGURE  
Figure 1 Study Design  ...............................................................................................................................................  16 
  
DocuSign Envelope ID: 

Vaxart I
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL                                                                                                                                                                   Page 9 of 106 
 LIST OF ABBREVIATIONS [AND DEFINITIONS OF TERMS]  
Term Description  
AE Adverse event  
AESI  Adverse event of special interest  
AEFI  Adverse events following immunization  
AGE Acute gastroenteritis  
ANCA  Anti-neutrophil cytoplasmic antibody  
ASC Antibody secreting cells  
BMI Body mass index  
CBER  Center for Biologics Evaluation and Research – FDA 
DP Drug product  
eCRF  Electronic case report form  
CFR Code of Federal Regulation  
CIOMS  Council for International Organizations of Medical Sciences  
CMP  Clinical Monitoring Plan  
CSR Clinical Study Report  
DCC Data Coordinating Center  
EOS End of Study  
ET Early Termination  
EUA  Emergency Use Authorization  
FDA Food and Drug Administration  
FSH Follicle stimulating hormone  
GCP Good Clinical Practice  
GI.1 Norovirus genogroup I.1  
GII.4  Norovirus genogroup II.4  
GMP  Good Manufacturing Practice  
GRAS  Generally recognized as safe  
HBsAg  Hepatitis B surface antigen  
HBGA  Histo -blood group antigen  
HCV  Hepatitis C virus  
HDPE  High -density polyethylene  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human immunodeficiency virus  
IB Investigator’s brochure  
ICF Informed Consent  
ICH International Conference on Harmonisation  
DocuSign Envelope ID: 

Vaxart I
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL                                                                                                                                                                   Page 10 of 106 
 IP  Investig ational Product  
ITT Intent to treat  
SMC  Safety Monitoring Committee  
IEC Independent Ethics Committee  
IgA Immunoglobulin A  
IgG Immunoglobulin G  
IND Investigational new drug  
IRB Institutional Review Board  
IU International units  
LAR Legally Accepted Representative  
MedDRA  Medical Dictionary for Regulatory Activities  
MOP  Manual of Procedures  
MSD  Meso Scale Discovery  
NOCI  New Onset of Chronic Illness  
NoV  Norovirus   
OHRP  Office for Human Research Protections  
PBMC  Peripheral blood mononuclear cells  
PVP Polyvinyl pyrrolidone  
PI Principal investigator  
RNA  Ribonucleic acid  
SAE Serious adverse event  
SAP Statistical analysis plan  
SARS -CoV-2 Severe acute respiratory syndrome coronavirus 2  
SoA Schedule of Activities  
SUSAR  Serious unexpected suspected adverse reaction  
TEAE  Treatment -emergent adverse event  
VP1 Vaccine Protein 1, major capsid protein of norovirus  
WHO  World Health Organization  
 
 
 
 
  
DocuSign Envelope ID: 

Vaxart I
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL                                                                                                                                                                   Page 11 of 106 
 1. Protocol synopsis  
Trial Title: A phase 2, multicenter, randomized, double -blind, placebo -controlled, single  dose, dose -ranging 
study to determine the safety and immunogenicity of bivalent GI.1 and GII.4 vaccine administered orally to 
healthy volunteers aged ≥ 18 years and ≤ 80 years old . 
Sponsor:  Vaxart, Inc.  
                 170 Harbor Way, Suite 300  
                 South San Francisco, CA 94080  
Contract Research Organization:    
 
  
 
 
  
 
Protocol number  VXA -NVV -202 IND Number  BB-IND 16796  
Trial Blinding scheme  Double -blind  Phase of study  2 
Trial Arms:  
Arm 1: Bivalent GII.4/GI.1 medium dose vaccine (VXA -GII.4 -NS plus VXA -G1.1 -NN) 5×1010 tablets; total 
dose is 1×1011 IU/dose ( n=50) 
Arm 2: Bivalent GII.4/GI.1 high dose vaccine (VXA -GII.4 -NS plus VXA -G1.1 -NN) 1×1011 tablets; total dose 
is 2×1011 IU/dose ( n=50) (sentinel  n=10)  
Arm 3: Placebo tablets ( n= 25) 
Description of Investigational Product:  
Name of Vaccine : Bivalent GI.1 and GII.4 vaccines (VXA -G1.1 -NN plus VXA -GII.4 -NS) 
• Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1 -/E3-Deleted Replication Defective 
 Recombinant Adenovirus 5 with dsRNA Adjuvant (VXA -G1.1 -NN) 
• Norovirus GII.4 Sydney VP1 Vaccine, Oral E1 -/E3-Deleted Replication Def ective 
 Recombinant Adenovirus 5 with dsRNA Adjuvant (VXA -GII.4 -NS) 
Dose Regimen : 5×1010 IU and 1×1011 IU per strain per dose  
Route : Oral  
Dosage Form : Tablet  
DocuSign Envelope ID: 

Vaxart I
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL                                                                                                                                                                   Page 12 of 106 
 This study will investigate the safety and immunogenicity of two monovalent Norovirus ( NoV ) oral t ableted 
vaccine candidates co -administered (bivalent delivery) against a matching placebo arm. All lots of Drug 
Product (DP) will be provided as small white enteric -coated tablets.   
VXA -G1.1 -NN and VXA -GII.4 -NS are E1/E3 -deleted, replication -incompetent, adenovirus 5 vaccine vectors 
designed for use as vaccines for prevention of  NoV infection. The vaccine vectors encode for a full -length 
VP1 gene of either Norwalk virus (VXA -G1.1 -NN vaccine) or Sydney virus (VXA -GII.4 -NS vaccine). In 
addition to the trans gene cassette, a second hCMVie promoter is also present in the vaccine constructs which 
is used to express a ribonucleic acid ( RNA ) sequence that acts as an adjuvant. The adjuvant is a short hairpin 
RNA expressed off a promoter such that only target cells in the intestine that express antigen will also express 
the adjuvant. This is likely to result in a tight association of antigen with adjuvant in vivo.  
Multiple tablets of study intervention  will be dispensed to allow delivery of the intended vaccine dose. A 
matching number of placebo tablets will be dispensed to maintain the study blinding.  
Subject Population:  
Ten (10) sentinel healthy  adult male and female subjects aged ≥ 18 years and ≤ 80 years will be enrolled into 
an open label portion of the study.  
One hundred and twenty -five (125)  healthy adult male and female subject s aged ≥  18 years  and ≤ 80 years 
will be enrolled in a double -blind randomized portion of the study.  
Objectives:  
Primary Objective :  
To determine the safety and immunogenicity of a bivalent dosing regimen of GI.1 and GII.4, to select the 
dose level with which to safely proceed into Phase 3 development . 
Endpoints:  
Primary End points :  
Safety: 
• Frequency, duration, and severity of Solicited Symptoms of Reactogenicity ( GI and systemic ) 
for 1 week following study intervention  dose 
• Frequency, duration, and severity of unsolicited adverse events (AEs) for 28 days following the 
study intervention  dose 
Immunogenicity:  
• Serum - Anti-VP1 GI.1 IgA and Anti -VP1 GII.4 IgA  by Meso  Scale Discovery (MSD) assay by 
dose level  
o geometric mean concentration (GMC) at Day 1 and Day 29  
o geometric mean fold rise (GMFR) from Day 1 to Day 29  
 
DocuSign Envelope ID: 

Vaxart I
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL                                                                                                                                                                   Page 13 of 106 
 • Serum - Anti-VP1 GI.1 IgG and Anti -VP1 GII.4 IgG  by Meso Scale Discovery (MSD) assay by 
dose level  
o geometric mean concentration (GMC) at Day 1 and Day 29  
o geometric mean fold rise (GMFR) from Day 1 to Day 29  
 
• Serum - Antibody BT50 titers for both GI.1 and GII.4  by Histo -blood group antigen (HBGA) 
Assay   
o geometric mean titer (GMT) Day 1 and Day 29  
o geometric mean fold rise (GMFR) from Day 1 to Day 29  
Exploratory End points: 
Safety: 
• Frequency, duration, and severity of serious adverse event (SAEs), adverse event of special 
interest (AESIs) and New Onset of Chronic Illness (NOCIs)  for 1 year following the study drug 
dose 
Immunogenicity:  
• Serum - Anti-VP1 GI.1 IgA and Anti -VP1 GII.4 IgA  by Meso Scale Discovery (MSD) assay by 
dose level  
o geometric mean concentration (GMC) at Day 8 and Day 180  
o geometric mean fold rise (GMFR) from Day 1 to Day 8 and from Day 1 to Day 180  
 
• Serum - Anti-VP1 GI.1 IgG and Anti -VP1 GII.4 IgG  by Meso Scale Discovery (MSD) assay by 
dose level  
o geometric mean concentration (GMC) at Day 8 and Day 180  
o geometric mean fold ri se (GMFR) from Day 1 to Day 8 and from Day 1 to Day 180  
 
• Serum - Antibody BT50 titers for both GI.1 and GII.4  by Histo -blood group antigen (HBGA) 
Assay   
o geometric mean titer (GMT) Day 8 and Day 180  
o geometric mean fold rise (GMFR) from Day 1 to Day 8 and from Day 1 to Day 180  
 
• Nasal Swab – Anti-VP1 GI.1 IgA and Anti -VP1 GII.4 IgA  
o geometric mean concentration (GMC) at Day 1, Day 8, Day 29 and Day 180  
o geometric mean fold rise (GMFR) from Day 1 to Day 8, Day 1 to Day 29 and from Day 
1 to Day 180  
 
• Saliva – Anti-VP1 GI.1 IgA and Anti -VP1 GII.4 IgA  
o geometric mean concentration (GMC) at Day 1, Day 8, Day 29 and Day 180  
o geometric mean fold rise (GMFR) from Day 1 to Day 8, Day 1 to Day 29 and from Day 
1 to Day 180  
 
• Fixed Whole Blood (required for blood d raw, optional for testing)  
o B-cell immunophenotyping at Day 1 and Day 8   
 
DocuSign Envelope ID: 

Vaxart I
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL                                                                                                                                                                   Page 14 of 106 
 Trial Rationale  
An effective NoV  vaccine must prevent the two most common NoV  genotypes, GI.1 and GII.4. This vaccine 
consists of VXA -G1.1 -NN and VXA -GII.4 -NS; the dose of the vaccine is 5×1010 IU and 1×1011 IU per strain 
per dose. GI.1/GII.4 bivalent vaccine is used to prevent illness from NoV . 
Noroviruses are a genetically diverse group of small, non -enveloped, single -stranded positive sense 
Ribonucleic acid ( RNA ) viruses belonging to the Caliciviridae  family. Norovirus infections are a leading 
cause of sporadic and epidemic gastroenteritis across all age groups worldwide. There is an urgent public 
health need for rapid development of novel interventions to prevent the spread of this disease, including 
proph ylactic measures, such as vaccines.  
A unique and advantageous immune response elicited by oral vaccination is the induction of antibodies 
derived from mucosal cells. Given that the mucosal route of immunization produces superior mucosal 
immunity compared to injected vaccines, it is hypothesized that GI.1/GII.4 bivalent oral vaccine may enable 
higher degrees of mucosal protection against infection when compared to a parenteral immunization method   
The current Phase 2 dose confirmation study is designed to assess the safety and immunogenicity of 
GI.1/GII.4 bivalent vaccine with a single vaccine dose in healthy volunteers (≥18 years and ≤80 years).  
Description of Sites/Facilities  
This will be a multi -center trial conducted  in the United States of America . The name of Investigators and 
sites are provided on the site  -specific F orm FDA 1572 document. 
  
DocuSign Envelope ID: 

Vaxart I
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL                                                                                                                                                                   Page 15 of 106 
 Trial design  
This is a multi -center, double -blind, randomized, placebo -controlled, single dose regimen , dose  ranging study in 
healthy volunteers (≥18 years  and ≤80  years ). The study will enroll  10 sentinel subjects in an open label period  and 
randomize  125 subject s in three double -blind arms .  
After reviewing and signing an informed consent, the subject s will undergo screening assessments to determine study 
eligibility up to  a 45-day Screening Period.  
The first 10 sentinel subjects  will receive open label  high dose of active vaccine (2×1011 IU). If no dose -related 
toxicities are observed, and upon the recommendation of the Safety Monitoring Committee (SMC) following review 
of Day 1 through  Day 8 safety data, enrollment of the remaining subjects  will be initiated.  The sentinel subjects will 
be enrolled in a staggered design, in which no more than two (2) subjects are dosed per 24 -hours. All sentinel subjects 
will be observed on site, for safety at least 2 hours post dose.  After the ten (10) sentine l subjects have  completed Day 
8 post dose , and if no  dose-related  toxicities are observed, and upon the recommendation of the Safety Monitoring  
Committee (SMC) following review of safety data up to one week post dose,  enrollment of the randomized double -
blind study will be initiated.  While ten (10) subjects will be dosed in the sentinel group, to allow for dropouts, eight 
(8) subjects with complete safety data (defined as Day 1 to Day 8) will be enough to convene the SMC . 
If pre -established stopping rules are met, enrollment of subsequent subjects   will be halted until the SMC has 
completed the review of all available safety data and provides recommendation for further study conduct . 
On Day  1 of the randomized portion , subject s will be randomized in a 2:2:1 ratio to one of the three treatment arms to 
receive active vaccine or placebo, as follows ( Figure  1): 
DocuSign Envelope ID: 

Vaxart I
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL                                                                                                                                                                   Page 16 of 106 
 Figure 1 Study Design    
 
After  vaccination on Day 1, the study will include an Active Study Period that runs  through 4 weeks  after 
administration (Day 29) , and a Follow -up Period of one year for safety and duration of immune response. Study 
assessments will be conducted as shown in the SoA (Table  1). In addition, subject s will be contacted by phone or 
app between site visits to monitor for safety as specified in the SoA  (Table  1). 
A subject  is considered to have completed the study if he/she  complete s the study active period at Day  29 (End of 
Study Active Period). Following completion of the Day  29 visit by all subject s the database will be cleaned and 
locked and the study unblinded . The Clinical Study Report (CSR) will be written based on the Day  29 dataset.   
A subject  is considered to have completed the Follow -up Period if he/she  remain s in the study through Day  365 
(Month 1 2). Following completion of the Day  365 a tele-health appointment  will be conducted for all subject s, the 
safety database will be cleaned and locke d, and data collected during the Follow -up Period will be  included in a 
CSR addendum . 
All subject s will be monitored for Solicited Symptoms of Reactogenicity  (GI and systemic  both) for 1 week 
following the study drug dose (until Day 8  (+2 days ) -scheduled site visit  (the sentinel subjects do not have a Day 8 
(+2) window )).  and unsolicited AEs for 28  days post study drug dose (until Day  29-scheduled site visit) ) during the 
Active Period.  The subject s will then enter the Follow -up Period after Day  29 and will be monitored for SAEs, 
AESIs , and NOCIs  through Day 365 (Month 1 2) for safety and duration of immune response. Subject s will also 
have samples collected for evaluation of  immunogenicity as specified in the SoA  (Table 1) .  
DocuSign Envelope ID: 

Vaxart I
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL                                                                                                                                                                   Page 17 of 106 
 Planned Number of Subjects:  
A total of 10 healthy adult male and female subjects  aged ≥18 years and ≤80 years will be enrolled  to the high dose 
investigational vaccine during t he open label portion of this study.  
A total of 125 healthy adult male and female subject s aged ≥18 years and ≤80 years will be, randomized , in a 2:2:1 
fashion, to receive the investigational vaccine or placebo  during this study.  
Eligibility Criteria  
Inclusion Criteria:  
To be eligible for this study, subject s must meet all the following:  
Age 
1. ≥18 to ≤80 years old inclusive at the time of signing the Informed Consent Form (ICF).  - 
Type of Subjects 
2. In stable and good general health, without significant medical illness, based on medical history, 
physical examination,  and vital signs at screening  based on investigator judgement .  
3. Body mass index (BMI) > 17.0 and < 35.0 kg/m2 at screening .  
4. Available for all planned visits and tele-health appointment s, and willing to complete all protocol -
defined procedures and assessments (including ability and willingness to swallow multiple small 
enteric -coated tablets per study dose).  
Gender and Reproduct ive Considerations  
5. Male or female subject s 
a. Female subject s must not be breastfeeding and must provide a negative pregnancy test at screening and 
pre-dose.  
b. Female subject s must fulfill one of the following criteria:  
i. At least 1 year post-menopausal (defined as amenorrhea for ≥  12 consecutive months prior to 
screening without alternative medical cause) or surgically sterile.  
ii. Female subject s of childbearing potential must be willing to use a highly effective form of 
contraception for 30  days prior to initial vaccination and until 60  days after last vaccination. 
Acceptable forms are oral, implantable, intrauterine, transdermal, intravaginal, injectable, 
double barrier or abstinence  (subjects using diaphragms must also use condom) . The for m of 
contraception must be approved by the investigator.  
iii. Male subject s must agree to refrain from donating sperm and practice abstinence from all 
intercourse or to use an effective method of double barrier birth control or condom as noted 
above from first  vaccination to 60 days after last vaccination.  
Informed Consent  
6. Capable of understanding and giving signed informed consent which includes compliance with the 
requirements and restrictions listed in the ICF and in the protocol.  
DocuSign Envelope ID: 

Vaxart I
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL                                                                                                                                                                   Page 18 of 106 
 Exclusion Criteria:  
The subject s must be excluded from participating in the study if they meet any of the following:  
1. Known clotting/bleeding issues and /or personal and family history with increased risk  of bleeding or 
clotting.  
2. Presence of significant uncontrolled m edical or psychiatric illness (acute or chronic) including institution of 
new medical/surgical treatment or significant dose alteration for uncontrolled symptoms or drug toxicity 
within 3  months prior to screening and reconfirmed at baseline.  
3. Cancer, or tr eatment for cancer or any procedure or preventive medication for cancer or to prevent 
recurrence within past 3  years (excluding fully treated and resolved basal cell carcinoma or squamous cell 
carcinoma) . 
4. Presence of immunosuppression or medical condition possibly associated with impaired immune 
responsiveness, including diabetes mellitus - type 1 and 2. 
5. Left blank intentionally.  
6. History of irritable bowel disease or other inflammatory digestive or gastrointestinal condition that could 
affect the distribution/safety evaluation of an orally administered vaccine targeting the mucosa of the small 
intestine. Such conditions may include but are not limited to:  
a. Any history of:  
i. GI malignancy  
ii. malabsorption  
iii. pancreatobiliary disorders  
iv. inflammatory bowel disease  
v. irritable bowel disease  
vi. hiatal hernia  
vii. surgical resection  
b. History of diagnosis or treatment in past 5 years of:  
i. esophageal or gastric motility disorder  
ii. gastroesophageal reflux disorder   
iii. peptic ulcer  
iv. cholecystectomy  
7. History of any form of angioedema . 
8. History of serious reactions to vaccination such as anaphylaxis, respiratory problems, hives or abdominal 
pain. 
9. Diagnosed bleeding disorder or significant bruising or bleeding difficulties that could make blood draws 
problematic . 
10. Any condition that resulted in the absence or removal of the spleen . 
11. Acute disease within 72  hours prior to vaccination defined as the presence of a moderate or severe illness 
(as determined by the investigator through medical history and phys ical exam). (Assessment may be 
repeated once during screening period) . 
12. Presence of a fever ≥38 .0 °C measured orally at baseline.  
13. Any significant hospitalization within the last year which in the opinion of the investigator or sponsor could 
interfere with study participation.  
14. Any of the following history or conditions that may lead to higher risk of clotting  events and/or 
thrombocytopenia:  
a. Family or personal history of bleeding or thrombosis . 
b. History of heparin -related thrombotic events, and/or receiving heparin treatments . 
c. History of autoimmune or inflammatory disease.  
d. Presence of any of the following conditions known to increase risk of thrombosis within 6  months 
prior to screening:  
i. Recent surgery other than removal/biopsy of cutaneous lesio ns. 
ii. Immobility (confined to bed or wheelchair for 3 or more successive days) . 
DocuSign Envelope ID: 

Vaxart I
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL                                                                                                                                                                   Page 19 of 106 
 iii. Head trauma with loss of consciousness or documented brain injury . 
iv. Receipt of anticoagulants for prophylaxis of thrombosis . 
v. Recent clinically significant infection . Including  hospitalization for COVID -19 infection.  
15. Any other condition that in the clinical judgement of the investigator would jeopardize the safety or rights 
of a subject  taking the study drug, would render the subject  unable to comply within the protocol or would 
interfere with the evaluation of the study endpoints diagnostic assess ments . 
16. Positive human immunodeficiency virus (H IV), Hepatitis B surface antigen (HBsAg) or Hepatitis C virus 
(HCV) tests at the screening v isit. 
17. History of GI bleeding including hematochezia (blood in stool) or melena (black stool) . 
18. Positive urine drug screen for drugs of abuse at screening (positive test for marijuana is not exclusionary; 
however concurrent use of marijuana during the study Active period through Day 29 is prohibited) . 
19. Positive breath or urine alcohol test at screening and baseline . 
Prior/Concurrent Therapy  
20. Receipt of a licensed vaccine (including any COVID -19 vaccines under Emergency Use Authorization) 
within 14  days prior to baseline vaccination or planned administration during the study active period 
(Day  29). 
21. Use of antibiotics, proton pump inhibitors, H2 blockers or antacids within 7  days prior to study drug 
administration or planned use during the active study per iod (Day  29). 
22. Use of medications known to affect the immune function ( including but not limited to  systemic 
corticosteroids , leukotriene modifiers, and  JAK inhibitors ) within 2 weeks before study drug administration 
or planned use during the active study p eriod (Day  29). 
23. Daily use of nonsteroidal anti -inflammatory drugs within7 days prior to study drug administration or 
planned use during the active study period (Day  29). Low dose daily ASA ≤ 100 mg for cardio -protection 
is not exclusionary.  
24. Administration of any investigational vaccine, drug or device within  8 weeks preceding study drug 
administration, or planned use within the duration of the study . 
25. Previous participation in a Vaxart  Clinical Trial or other norovirus vaccine trial unless confirmed receipt of 
placebo  
Other Exclusions  
26. Donation or use of blood or blood products within 30 days prior to study drug administration or planned 
donation during the active study period (Day29) . 
27. History of drug, alcohol,  or chemical abuse within 1 year of screening . 
28. History of hypersensitivity or allergic reaction to any component of the investigational vaccine, including 
but not limited to fish gelatin allergy . 
 
Study Duration:  
For each subject , study participation is expected to last as follows:  
Open Label  Period (for sentinel subjects)  8 days  (staggered dosing and collection of Solicited 
Symptoms ) and then continue through Active and 
Follow Up Period  enrolled in an open labe l portion.  
Screening period:  Up to 45 days  
Active study period for reactogenicity,  
safety , and  immunogenicity  29 days  
DocuSign Envelope ID: 

Vaxart I
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL                                                                                                                                                                   Page 20 of 106 
 Follow Up Period for safety and duration 
of immune response , SAEs, AESIs, NOCIs  12 months (from last study dose at Day  365) 
Total duration:  12 months  
 
Statistical Method:  
The statistical analysis plan (SAP) will be developed and finalized before database lock for any of the planned 
analyses. It will describe the subject  populations to be included in the analyses and the procedures for accounting for 
missing, unused, and spurious data. This section provides a summary of the planned statistical analyses of the 
primary endpoints .  
Sample Size Justification  
A sample size of  125  randomized subject s (50 each in medium and high dose levels  and 25 in placebo) in addition 
to 10 sentinel subjects are not based on formal statistical testing but rather based on clinical judgement and predicted 
to yield meaningful safety and immunogenicity results . Placebo was added for safety comparison.  
The numbers of subject s per dose group are predicted to yield meaningful safety and immunogenicity results .  
Interim Analysis   
No interim analysis will be conducted for this study.  
Safety Monitoring Committee:  
A safety monitoring committee will be assigned by the Sponsor prior to the beginning of the study and will provide 
ongoing oversight of the study.  
Unblinded data may be provided to the SMC if required  during the double -blind period . Further details regarding 
data safety monitoring guidelines will be included in the SMC Charter.  
 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                                                                                                                                                                                                                        09 Feb 2023  
CONFIDENTIAL                                                                                                                                                                                                                                              Page 21 of 106 
 1.1 Schedule of Trial Activities  
Table 1: Schedule of Activities  
 Screening  Active Study Period  Follow-Up Period  
Study Day  Day -45 
to Day -1 Day 1  Day 8 
(+2 
Days)g Day 29/  
Early 
Termination  Month 2 
Day 60  Month 4 
Day 120  Month 6 
Day 180g Month 8 
Day 240  Month 10  
Day 300  Month 12  
Day 365 
Tele-health Appointment  X          
Visit Window (days)  X X  ±2 ±7 ±7 ±7 ±7 ±7 ±7 
Informed consent  X          
Inclusion/Exclusion  X X         
Demographics  X          
Medical history  X X         
Serologya X          
Urine drug screen  X          
Breath or urine alcohol  X X         
Pregnancy Test b X X         
Physical examination  X X* X* X*d       
Vital Signsc X X X Xd       
COVID-19 Vaccination Status  X          
Study Drug Administrationg  X         
Access to Solicited Symptom Diary 
/App  X         
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                                                                                                                                                                                                                        09 Feb 2023  
CONFIDENTIAL                                                                                                                                                                                                                                              Page 22 of 106 
 Review Solicited Symptom Diary 
/Appf    Xd Xd       
Review prior & concomitant 
medication  X X X Xd       
Query for AEs, SAEs, AESIs and 
NOCIs  X X Xd Xe Xe Xe Xe Xe Xe 
 
Sample Collection for Immunogenicity Assessments – All Subjects  
Study Day  Day -45 
to Day -1 Day 1  Day 8  Day 29/  
Early 
Termination  Month 2 
Day 60  Month 4 
Day 120  Month 6 
Day 180g Month 8 
Day 240  Month 10  
Day 300  Month 12  
Day 365 
Serum blood sample   X Xg Xd   X    
Nasal Swab   X Xg Xd   X    
Saliva Sample   X Xg Xd   X    
Fixed whole blood sample  (required 
for blood draw, optional for testing)   X Xg        
Abbreviations: Ab, Antibody; AE, adverse events; AESI, adverse event of special interest; ASC, Antibody secreting cells; BT 50, serum blocking antibody titers; 
EOS, End of Study (Active Period); ET, Early Termination; HBGA, histo -blood group antigen;  HBV, Hepatitis B Virus; HCV, Hepatitis C Virus; HIV, Human 
Immunodeficiency Virus; IgA, immunoglobulin A; IgG, immunoglobulin G; M SD, Meso Scale Discovery; NOCI, new onset chronic illness; SAE, serious 
adverse event; VP1, Vaccine Protein 1  
Notes:   Tele-health appointment (by app or by phone)    
*Targeted   
a Serology - Positive human immunodeficiency virus (H IV), Hepatitis B surface antigen (HBsAg) or Hepatitis C virus (HCV)  
b Serum pregnancy tests will be done at screening  on all women . Point -of-Care urine pregnancy test will be performed before dosing on Day 1 on all women, and 
women found positive with urine pregnancy test will not be enrolled during this study.  
c Temperature, b lood pressure, heart rate, and respiratory  rate w ill be measured after the subject  has been resting for 5 minutes  
d Early termination assessments  (Solicited Symptoms are to be captured if ET occurs prior to Day 8 ) 
e TEAEs will only be collected during the Active Study period (from time of first dose through 4 weeks post last dose). Only SAEs, AESIs and NOCIs will be 
collected during the Follow -up Period.  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                                                                                                                                                                                                                        09 Feb 2023  
CONFIDENTIAL                                                                                                                                                                                                                                              Page 23 of 106 
 f At the discretion of PI and/or per subject request to evaluate any of the expected reactogenicity symptoms  or any unexpected symptoms of concern, a con tact 
must occur as soon as possible  between the subject  and the Investigator, or a medically qualified member of the study site staff, to assess if an unscheduled visit 
is required  
g Open label subjects will continue through the active period and into the Follow -up Period  and have the same procedures as the randomized population  with the 
exception of the Day 8 bio -samples. The Day  8 bio-sampling is not applicable for sentinel subjects. The Day 8 window  (Day 8  (+2) is not applicable to the 
sentinel subjects.  The sentinel subjects will not have a Day 180 bio sample collected. As such the sentinel subjects will have a phone call visit to collect safety 
data.  
 
  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 24 of 106 
 
 2. INTRODUCTION  
2.1 Indication  
Bivalent GI.1 and GII.4 vaccine s are being investigated for the prevention of noroviral 
gastroenteritis caused by norovirus GI.1 and G II.4. 
2.2 Background 
2.2.1 Background of disease 
Norovirus (NoV) infection remains a leading cause of Acute gastroenteritis ( AGEs ) globally, with 
a prevalence of 16% (Liao et al., 2021 ). Noroviruses are a genetically diverse group of small, non -
enveloped, single -stranded positive sense (RNA ) viruses belonging to the Caliciviridae family 
(Bresee et al., 2002 ). Genogroups I, II and IV are human -transmitted. Genogroup I and II account 
for the majority of norovirus outbreaks  .Each genogroup is further divided into genotypes based 
on the similarity of the amino acid sequence of the major viral capsid protein, VP1  (Atmar and 
Estes, 2012 ). Genogroup I and II account for the majority of norovirus outbreaks (Vega et al., 
2014 ). The  classic symptoms of NoV infection include sudden onset of vomiting, abdominal 
cramps, watery diarrhea, and other clinical symptoms such as headache, chills, and myalgias.  
Currently, there is no specific treatment modality for NoV  infection. The standard treatment is oral 
rehydration with fluids and electrolytes  (Glass et al., 2009 ). In 2016, the World Health 
Organization  (WHO)  stated that the development of a NoV vaccine should be considered an 
absolute priority. It is important to develop prevention methods like vaccines considering the 
NoV -associated risk  (Esposito and Principi, 2020 ). Despite  a large medical need and years of 
development, no vaccine is licensed for use in any population for NoV infection.  
2.2.2 Non-clinical experience with Bivalent GI.1 and GII.4 vaccine 
Vaxart has conducted multiple preclinical studies of our norovirus vacci ne candidate in mice and 
ferrets , further details are available in the Investigator ’s Brochure . The preclinical and clinical data 
on VXA -G1.1 -NN and on influenza HA (with the same exact vector backbone) demonstrates a 
29-fold increase in neutralizing antibody responses after single dose enteric -coated tablet 
administration  (Liebowitz et al., 2020 ),   confi rming that VXA -G1.1- NN and VXA -GII.4 -NS are 
capable of eliciting robust antibody responses to VP1 following oral tablet delivery.  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 25 of 106 
 
 2.2.3 Clinical experience with Bivalent GI.1 and GII.4 vaccine 
Vaxart  has completed four Phase 1 studies in over 200 healthy volunteers with our monovalent 
tableted norovirus GI.1 oral tablet vaccine candidate and one Phase 1b study with our bivalent 
tableted vaccine candidate (co -administration of GI.1 and GII.4 vaccines).   In all studies, the 
primary endpoint was safety, and the secondary endpoint was immunogenicity. In the bivalent 
study potential interference with co -administration was also evaluated.  These studies indicate that 
the vaccine was safe and generally well tolerated and there have been no severe adverse events 
(SAEs) attributed to vaccine. The vaccine has  generated robust immune responses including 
systemic and mucosal antibodies as well asimmunoglobulin A + (IgA) and immunoglobulin G 
(IgG) + memory B cells. . In addition to increase in serum blocking titer fifty assay (BT50) titers, 
vaccine recipients also developed mucosally primed VP1 -specific circulating antibody secreting 
cells (ASCs), IgA+ memory B cells expressing gut -homing receptor (α4β7), a nd fecal IgA, 
indicating substantial and local responses potentially relevant to prevent norovirus infection  
(Kim-et al., 2018 ).  
During the Phase 1 dose-ranging study VXA -NVV -104, a total of 65 healthy adult volunteers ages 
55-80 ( in two age cohorts) were evaluated for  immunogenicity, safety, and tolerability at three 
dosing levels: low, medium or high.  Preliminary results  of this Phase 1  study indicate  this oral 
norovirus vaccine candidate was safe, well -tolerated, and induced similar immune responses in 
this older population compared to previous results in younger volunteers.  
In an open label  Phase 1b boost optimization study (VXA -NVV -105), immunogenici ty, safety and 
tolerability  of repeat -dose administration with varying boost schedules; were evaluated  in healthy 
adults (18 -55 years). VXA -GI.1 was found to be safe and generally well -tolerated in 4 -week, 8 -
week and 12 -week boost schedules. All solicited  symptoms were graded as mild or moderate 
severity, and none required treatment or study discontinuation .  During the active period there were 
no related unsolicited AEs and no related SAEs, AESI or NOCIs. There were no  SAEs, AESIs, 
or NOCIs reported during the safety follow -up period.  There were no deaths during the study. 
Clinical laboratory data, vital signs data, and physical examination findings were within normal 
ranges and those reporting deviations were mild and transient. No clinically significant  abnormal 
physical examination findings were noted. 
The Phase 2  (VXA -NVV -201) is an ongoing norovirus challenge monovalent GI.1 vaccine trial 
being conducted in healthy volunteers . Preliminary r esults obtained to date  during this study 
indicate vaccine safety  comparable to previous trials. . 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 26 of 106 
 
 2.3 Trial Rationale  
An effective NoV  vaccine must prevent the two most common NoV  genotypes, GI.1 and GII.4. 
This vaccine consists of VXA -G1.1- NN and VXA -GII.4 -NS;the dose of the vaccine is 5×1010 IU 
and 1×1011 IU per strain per dose. GI.1/GII.4 bivalent vaccine is used to prevent illness from NoV . 
Noroviruses are a genetically diverse  group of small, non -enveloped, single -stranded positive 
sense RNA viruses belonging to the Caliciviridae  family. Norovirus infections are a leading cause 
of sporadic and epidemic gastroenteritis across all age groups worldwide. There is an urgent public 
health need for rapid development of novel interventions to prevent the spread of this disease, 
including prophylactic measures, such as vaccines.  
A unique and advantageous immune response elicited by oral vaccination is the induction of 
antibodies derived from mucosal cells. Given that the mucosal route of immunization produces 
superior mucosal immunity compared to injected vaccines, it is hypothesized that GI.1/GII.4 
bivalent oral vaccine may enable higher degrees of mucosal protection against infection wh en 
compared to a parenteral immunization method.  
The current Phase 2 dose confirmation study is designed to assess the safety and immunogenicity 
of medium and high dose levels of GI.1/GII.4 bivalent vaccine with a single dose  vaccination 
schedule in health y volunteers (≥18 years  and ≤80 years ). 
2.4 Risk / Benefit Assessment   
2.4.1 Known Potential Risks to the Subjects 
More detailed information about the known and expected risks and reasonably expected adverse 
events of Bivalent GI.1/GII.4 NoV  vaccine may be found in the Investigator’s Brochure ( IB). 
Below are the expected TEAEs with Grade 1 -3 symptoms: 
1. Diarrhea  
2. Nausea  
3. Abdominal pain  
4. Malaise/fatigue  
5. Headache  
6. Fever  
7. Vomiting  
8. Anorexia 
9. Myalgia (muscle pain)  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 27 of 106 
 
 2.4.2 Known Potential Benefit s to the subject 
Benefits to individual subject s may include receipt of a potentially efficacious NoV  vaccine. 
Clinical data from Phase 1 studies demonstrated that VXA -G1.1- NN generated robust immune 
responses.  
Since these are experimental vaccines against NoV , there are no proven benefits to the subje cts for 
their participation in this research study.  This vaccine may successfully  be developed to address a 
common and sometimes serious gastrointestinal infection.  
2.4.3 Overall Benefit Risk Conclusion  
Taking into account the measures taken to minimize risk to subjects participating in this study, 
the potential risks identified in association with Bivalent GI.1/GII.4 NoV  vaccine are justified by 
the anticipated benefits that may be afforded to subject s with noroviral gastroenteritis caused by 
NoV  GI.1 and GII.4. 
3. TRIAL OBJECTIVE AND END POINTS  
3.1 Objectives  
3.1.1 Primary Objectives  
To determine the safety and immunogenicity of a bivalent dosing regimen of GI.1 and GII.4, to 
select the dose level and regimen with which to safely proceed into Phase 3 development. 
3.2 End Points  
3.2.1 Primary End Points  
Safety: 
• Frequency, duration, and severity of Solicited Symptoms of Reactogenicity ( GI and 
systemic ) for 1 week following each study drug dose. 
• Frequency, duration, and severity of unsolicited adverse events (AEs) for 28 days 
following last study drug dose. 
 
 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 28 of 106 
 
 Immunogenicity:  
• Serum - Anti-VP1 GI.1 IgA and Anti -VP1 GII.4 IgA  by Meso  Scale Discovery (MSD) 
assay by dose level  
o geometric mean concentration (GMC) at Day 1 and Day 29  
o geometric mean fold rise (GMFR) from Day 1 to Day 29  
 
• Serum - Anti-VP1 GI.1 IgG and Anti -VP1 GII.4 IgG  by Meso  Scale Discovery (MSD) 
assay by dose level 
o geometric mean concentration (GMC) at Day 1 and Day 29  
o geometric mean fold rise (GMFR) from Day 1 to Day 29  
 
• Serum - Antibody BT50 titers for both GI.1 and GII.4  by Histo -blood group antigen 
(HBGA) Assay    
o geometric mean titer (GMT) Day 1 and Day 29  
o geometric mean fold rise (GMFR) from Day 1 to Day 29  
3.2.2 Exploratory End Points  
Safety: 
• Frequency, duration, and severity of SAEs, AESIs and NOCIs for 1 year 
following last study drug dose. 
 
Immunogenicity : 
• Serum - Anti-VP1 GI.1 IgA and Anti -VP1 GII.4 IgA  by Meso Scale Discovery (MSD) 
assay by dose level 
o geometric mean concentration (GMC) at Day 8 and Day 180 
o geometric mean fold rise (GMFR) from Day 1 to Day 8 and from Day 1  to Day 
180 
 
• Serum - Anti-VP1 GI.1 IgG and Anti -VP1 GII.4 IgG  by Meso Scale Discovery (MSD) 
assay by dose level 
o geometric mean concentration (GMC) at Day 8 and Day 180 
o geometric mean fold rise (GMFR) from Day 1 to Day 8 and from Day 1 to Day 
180 
 
• Serum - Antibody BT50 titers for both GI.1 and GII.4  by Histo -blood group antigen 
(HBGA) Assay    
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 29 of 106 
 
 o geometric mean titer (GMT) Day 8 and Day 180  
o geometric mean fold rise (GMFR) from Day 1 to Day 8 and from Day 1 to Day 
180 
 
• Nasal Swab – Anti-VP1 GI.1 IgA and Anti-VP1 GII.4 IgA 
o geometric mean concentration (GMC) at Day 1, Day 8, Day 29 and Day 180 
o geometric mean fold rise (GMFR) from Day 1 to Day 8, Day 1 to Day 29 and 
from Day 1 to Day 180 
 
• Saliva – Anti-VP1 GI.1 IgA and Anti-VP1 GII.4 IgA 
o geometric mean concentration (GMC) at Day 1, Day 8, Day 29 and Day 180 
o geometric mean fold rise (GMFR) from Day 1 to Day 8, Day 1 to Day 29 and 
from Day 1 to Day 180 
 
• Fixed Whole Blood (required for blood draw, optional for testing)  
o B-cell immunophenotypin g at Day 1 and Day 8   
 
4. TRIAL DESIGN  
4.1 Overall Description of Trial Design   
This is a multi -center, double -blind, randomized, placebo -controlled, single dose, dose ranging 
study in healthy volunteers (≥18 years  and ≤80 years ). The study will enroll 10 sentinel subjects 
in an open label period and randomize 125  subject s in three arms .  
After reviewing and signing an informed consent, the subject s will undergo screening assessments 
to determine study eligibility up to a 45-day Screening Period.  
The first 10 sentinel subjects, in a staggered manner of up to 2 subjects per 24-hour period, will 
receive the open label high dose of bi- valent active vaccine (2×1011) shown in  Table 2. If no dose-
related toxicities are observed, and upon the recommendation of the SMC following review of safety 
data, enrollment of the randomized double-blind s tudy will be initiated.  
 
 
 
 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 30 of 106 
 
 Table 2:  Sentinel Subjects  
Treatment 
Group  Study 
drug Per Strain Dose 
(IU) Total Dose 
(IU/dose)  Dosing 
Schedule  No of 
Subjects  
Open label  Bivalent  
GII.4/GI.1 
vaccine  1×1011 2×1011 Day 1  2 
Open label  Bivalent  
GII.4/GI.1 
vaccine  1×1011 2×1011 * 3-10 
*Two (2) subjects can be dosed in a staggered manner, at least 24 hours from the dosing date of the 
last 2 subjects  
If pre -established stopping rules are met, enrollment of subsequent subject s will be halted until the 
SMC has completed the review of all available safety data and provides recommendation for 
further study conduct. 
On Day  1 of the double-blind portion , subjects will be randomized in a 2:2:1 ratio to one of the 3 
study arms to receive active vaccine or placebo, as follows (Table 3): 
Table 3: Study Design  
Treatment 
Group Study drug   Per Strain Dose 
(IU) Total Dose 
(IU/dose) Dosing Schedule  No of Subjects 
Sentinel 
Open Label  Bivalent 
GII.4/GI.1 
vaccine 1×1011 2×1011 Day 1 10 
Arm 1 Bivalent 
GII.4/GI.1 
vaccine  5×1010 1×1011  Day 1  50 
Arm 2 Bivalent 
GII.4/GI.1 
vaccine  1×1011 2×1011 Day 1  50 
Arm 3 Placebo  N/A N/A Day 1  25 
Total  135 
Abbreviations: IU=infectious units; N/A=not applicable  
After  vaccination on Day  1, the study will include an Active Study Period that runs through 4 
weeks after administration  (Day  29), and a Follow -up Period of one year for safety and duration 
of immune response. Study assessments will be conducted as shown in the SoA (Table 1). In 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 31 of 106 
 
 addition, subject s will be contacted by phone or app between site visits to monitor for safety as 
specified in the SoA (Table  1). 
A subject  is considered to have completed the study if he/she complete s the study active period at 
Day 29 (End of Study Active Period). Following completion of the Day  29 visit by all subject s the 
database will be cleaned and locked and the study unblinded. The Clinical Study Report (CSR will 
be written based on the Day 29 dataset.  
A subject  is considered to have completed the Follow -up Period if he/she  remain s in the stud y 
through Day  365 (Month 1 2). Following completion of the Day  365 a tele -health appointment 
phone contact will be conducted for  all subject s, the safety database will be cleaned and locked, 
and data collected during the Follow-up Period will be included in a CSR addendum. 
All subject s will be monitored for Solicited Symptoms of Reactogenicity ( GI and systemic  both) 
for 1 week following the study drug dose and unsolicited AEs for 28 days post study drug dose 
(until Day 29) during the active period. The subject s will then enter the Follow -Up Period after 
Day 29 and will be monitored for serious adverse events  (SAEs), AEs of special interest (AESIs), 
and new onset of chronic illness (NOCIs) through Day 365 (Month 1 2) for safety. Subject s will 
also have samples collected for evaluation of immunogenicity and duration of immune response 
as specified in the SoA  (Table 1). 
Planned Number of Subjects:  
A total of 10 healthy adult male and female subjects aged ≥18 years and ≤80 years will be enrolled 
to the high dose investigational vaccine during the open label sentinel , first portion of this study. 
A total of 125 healthy adult male and female subjects aged ≥18 years  and ≤80 years are planned 
to be randomized in one of three study arms, post SMC assessment of safety is complete, and the 
decision post SMC is favorable towards starting the randomized, second portion of this study to 
investigational vaccine  or placebo during this study. 
Study Duration:  
For each subject, study participation is expected to last as follows:  
  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 32 of 106 
 
 Table 4: Study Duration  
Screening period:  Up to 45 days  
Open Label  Period  (for 10 sentinel subjects)  8 days  (staggered dosing and collection of Solicited 
Symptoms and continue through Active and Follow 
Up Period)  
Randomized Period (for 125 randomized subjects  8 days (dosing and collection of Solicited 
Symptoms ) and continue through Active  (Day 29 )  
and Follow  Up Period  (Day 30 -Day 365 ) 
  
Active study period for primary immunogenicity and 
safety  29 days  
Follow Up Period for safety and duration of immune 
response  12 months (from study dose at Day  1) 
Total duration:  12 months  
4.2 Scientific Rationale of Trial Design  
This study is designed as a standard double -blind placebo -controlled single  administration , dose -
ranging study to evaluate the effect of 2 different doses (high and medium dose) of VXA -GII.4 -
NS plus VXA -G1.1- NN in the target population, compared with placebo. 
4.3 Justification for dose selection  
Vaxart has previously completed dose escalation (Protocol VXA -G11-101) and dose optimization 
(Protocol VXA -G11-102) studies in its initial Phase 1 NoV vaccine studies to demonstrate the 
safety, tolerability and immunogenicity of the VXA -G1.1- NN vaccine candidate. A Phase 1b, 
double- blind, placebo -controlled study (Protocol VXA -NVV -103) with VXA -G1.1- NN and 
VXA -GII.4 -NS with monovalent or bivalent dosing have also been completed. Additionally, dose 
ranging studies from 1 ×108 IU – 1×1011 IU (2 doses) have been studied across multiple studies 
with the same vaccine platform  in subjects up to age 80 
Safety results from these completed oral tablet vaccine studies support investigations of bivalent 
administration of the VXA -G1.1- NN and VXA -GII.4 -NS vaccine candidates at single total dose 
of 1×1011 IU per vaccine or 2×1011 IU per administration.  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 33 of 106 
 
 4.4 End of the study definition  
A subject  is considered to have completed the study if he/she complete s the study active period at 
Day 29 (End of Study Active Period). Following completion of the Day  29 visit by all subject s the 
database will be cleaned and locked , and the study unblinded. The CSR will be written based on 
the Day 29 dataset.  
A subject  is considered to have completed the Safety Follow -up Period if he/she remain s in the 
study Day 365 (Month 12 ). Following completion of the Day 365 tele-health appointm ent of all 
subject s, the safety database will be cleaned and locked , and data collected during the Follow -Up 
Period will be  used to generate a  CSR addendum. 
4.5 Premature Termination or Suspension of Trial  
The Sponsor or designee reserves the right to terminate the study at any time for any reason at the 
sole discretion of the Sponsor. This trial may be temporarily suspended or prematurely terminated 
if there is sufficient reasonable cause. Written notification, documenting the reason for trial 
suspension or termination, will be provided by the suspending or terminating party to study 
subjects, Investigator s, funding agency, the Investigational New Drug (IND) Sponsor and 
regulatory authorities. If the study is prematurely terminated or suspended, the site Principal 
Investigator (PI) will promptly inform study subject s, the site Institutional Review Board (IRB)  (if 
applicable) and will provide the reason(s) for the termination or suspension. Study subject s will be 
contacted, as applicable, and be informed of changes if any , to the study visit schedule.  
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to subjects 
• Demonstration of efficacy that would warrant stopping  
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable  
• Determination that th e primary endpoint has been met 
• Determination of futility  
Study may resume once concerns about safety, protocol compliance, and data quality are 
addressed, and satisfy the Sponsor, IRB /IEC , Food and Drug Administration (FDA)  and/or New 
Zealand Medicines an d Medical Devices Safety Authority . 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 34 of 106 
 
 4.6 Trial and Site Start and Close-Out  
4.6.1 First Act of Recruitment  
The study start date is the date on which the clinical study will be open for recruitment of 
subjects. The first act of recruitment is the first site open  and will be the study start date.  
4.6.2 Study/Site Termination  
The Sponsor or designee reserves the right to close the study site at any time for any reason at the 
sole discretion of the Sponsor. Study sites will be closed upon study completion. A study site is 
considered closed when all required documents and study suppli es have been collected and a 
study- site closure visit has been performed.  
The Investigator  may initiate study -site closure at any time, provided there is reasonable cause and 
sufficient notice is given to Sponsor and subjects in advance of the intended ter mination.  
Reasons for the early closure of a study site by the Sponsor or Investigator may include but are not 
limited to:  
• Failure of the Investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the Sponsor’s procedures, or GCP guidelines. 
• Inadequate or no recruitment (evaluated after a reasonable amount of time) of 
subjects by the Investigator. 
• Total number of subjects included is archived earlier than expected . 
 
The Investigator  shall promptly inform the subject and should assure appropriate subject  therapy 
and/or follow -up. 
5. SELECTION OF TRIAL POPULATION  
5.1 Inclusion Criteria  
To be eligible for this study, subject s must meet all the following:  
Age 
1. ≥18 to ≤ 80 years old inclusive at the time of signing the Informed Consent Form 
(ICF).  
 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 35 of 106 
 
 Type of Subjects 
2. In stable and good general health, without significant medical illness, based on 
medical history, physical examination, and vital signs at screening based on 
investigator judgement.  
3. Body mass index (BMI) > 17.0 and < 35.0 kg/m2 at screening  . 
4. Available for all planned visits and tele-health appointment , and willing to complete 
all protocol -defined procedures and assessments (including ability and willingness to 
swallow multiple small enteric -coated tablets per study dose). 
Gender and Reproductive Considerations  
6. Male or female subject s 
a. Female subject s must not be breastfeeding and must provide a negative pregnancy 
test at screening and pre-dose.  
b. Female subject s must fulfill one of the following criteria:  
i. At least 1 year post-menopausal (defined as amenorrhea for ≥ 12 consecutive 
months prior to screening without alternative medical cause) or surgically 
sterile.  
ii. Female subject s of childbearing potential must be willing to use a highly 
effective form of contraception for 30  days prior to initial vaccination and 
until 60 days after last vaccination. Acce ptable forms are oral, implantable, 
intrauterine, transdermal, intravaginal, injectable, double barrier or abstinence 
(subjects using diaphragms must also use condom). The form of contraception 
must be approved by the investigator.  
iii. Male subject s must agre e to practice abstinence from heterosexual intercourse 
or to use an effective method of birth control as noted above from first 
vaccination to 60  days after last vaccination.  Male subject s must agree to 
refrain from donating sperm and practice abstinence f rom all intercourse or to 
use an effective method of double barrier birth control or condom as noted 
above from first vaccination to 60  days after last vaccination.  
Informed Consent  
6. Capable of understanding and giving signed informed consent which includes compliance 
with the requirements and restrictions listed in the ICF and in the protocol.  
 
 
 
 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 36 of 106 
 
 Exclusion Criteria  
The subject s must be excluded from participating in the study if they meet any of the following:  
1. Known clotting/bleeding issues and /or personal and family history with increased risk  of 
bleeding or clotting . - 
2. Presence of significant uncontrolled medical or psychiatric illness (acute or chronic) 
including institution of new medical/surgical treatment or significant dose alteration for 
uncontrolled symptoms or drug toxicity within 3 months prior to  screening and 
reconfirmed at baseline.  
3. Cancer, or treatment for cancer or any procedure or preventive medication for cancer or 
to prevent recurrence , within past 3 years (excluding fully treated and resolved basal cell 
carcinoma or squamous cell carcinoma)  
4. Presence of immunosuppression or medical condition possibly associated with impaired 
immune responsiveness, including diabetes mellitus- type 1 and 2 
5. Left blank intentionally. 
6. History of irritable bowel disease or other inflammatory digestive or gastrointestinal 
condition that could affect the distribution/safety evaluation of an orally administered 
vaccine targeting the mucosa of the small intestine . Such conditions may include but are 
not limited to: 
a. Any history of:  
i. GI malignancy  
ii. malabsorption  
iii. pancreatobiliary disorders 
iv. inflammatory bowel disease 
v. irritable bowel disease  
vi. hiatal hernia  
vii. surgical resection  
b. History of diagnosis or treatment in past 5 years of:  
i. esophageal or gastric motility disorder  
ii. gastro esophageal reflux disorder   
iii. peptic ulcer  
iv. cholecystectomy  
7. History of any form of angioedema 
8. History of serious reactions to vaccination such as anaphylaxis, respiratory problems, 
hives or abdominal pain 
9. Diagnosed bleeding disorder or significant bruising or bleeding difficulties that could 
make blood draws problematic 
10. Any condition that resulted in the absence or removal of the spleen  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 37 of 106 
 
 11. Acute disease within 72 hours prior to vaccination defined as the presence of a moderate 
or severe illness (as determined by the investigator through medical history and physical 
exam). (Assessment may be repeated once during Screening Period) 
12. Presence of a fever ≥38 .0°C measured orally at baseline.  
13. Any significant hospitalization within the last year which in the opinion of the 
investigator or sponsor could interfere with study participation. 
14. Any of the following history or conditions that may lead to higher risk of clotting  events 
and/or thrombocytopenia:  
a. Family or personal history of bleeding or thrombosis . 
b. History of heparin -related thrombotic events, and/or receiving heparin treatments . 
c. History of autoimmune or i nflammatory disease.  
d. Presence of any of the following conditions known to increase risk of thrombosis 
within 6  months prior to screening:  
i. Recent surgery other than removal/biopsy of cutaneous lesions 
ii. Immobility (confined to bed or wheelchair for 3 or more successive 
days) 
iii. Head trauma with loss of consciousness or documented brain injury  
iv. Receipt of anticoagulants for prophylaxis of thrombosis  
v. Recent clinically significant infection , including hospitalization for 
COVID -19 infection. 
15. Any other condition that in the clinical judgement of the investigator would jeopardize 
the safety or rights of a subject taking the study drug, would render the subject unable to 
comply within the protocol or would interfere with the evaluation of the stu dy endpoints 
diagnostic a ssessments . 
16. Positive human immunodeficiency virus (H IV), Hepatitis B surface antigen (HBsAg) or 
Hepatitis C virus (HCV) tests at the screening visit . 
17. History of GI bleeding including hematochezia (blood in stool) or melena (black stool) 
18. Positive urine drug screen for drugs of abuse at screening (positive test for marijuana is 
not exclusionary; however concurrent use of marijuana during the study Active period 
through Day 29 is prohibited) . 
19. Positive breath or urine alcohol test at sc reening and baseline . 
Prior/Concurrent Therapy  
20. Receipt of a licensed vaccine (including any COVID -19 vaccines under e mergency use 
authorization) within 14 days prior to baseline vaccination or planned administration 
during the study active period (Day  29). 
21. Use of antibiotics, proton pump inhibitors, H2 blockers or antacids within 7 days prior to 
study drug administration or planned use during the active study period (Day 29). 
22. Use of medications known to affect the immune function (e.g., including b ut not limited 
to systemic corticosteroids, leukotriene modifiers, and JAK inhibitors ) within 2 weeks 
before study drug administration or planned use during the active study period (Day 29). 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 38 of 106 
 
 23. Daily use of nonsteroidal anti- inflammatory drugs within7 days pr ior to study drug 
administration or planned use during the active study period (Day 29). Low dose daily 
ASA ≤ 100 mg for cardio-protection is not exclusionary. 
24. Administration of any investigational vaccine, drug or device within 8 weeks preceding 
study drug administration, or planned use within the duration of the study 
25. Previous participation in a Vaxart Clinical Trial or other NoV  vaccine trial unless 
confirmed receipt of placebo . 
Other Exclusions  
26. Donation or use of blood or blood products within 30 days prior to study drug 
administration or planned donation during the active study period (Day 29). 
27. History of drug, alcohol, or chemical abuse within 1 year of screening .  
28. History of hypersensitivity or allergic reaction to any component of the investigational 
vaccine, including but not limited to fish gelatin allergy . 
5.2 Early Termination/ Withdrawal criteria  
In case of Early Termination (ET)  prior to Day  8, all procedures marked as ‘early termination 
assessments ’ should be completed as shown in the SoA (Table  1). 
Subject s have the right to withdraw from the study at any time and for any reason without 
prejudice to their future medical care by the Investigator or at the institution. A subject may 
discontinue /withdraw  study drug for reasons including but not limited to: 
• Adverse event 
• Death  
• Lost to follow -up 
• Physician decision  
• Protocol deviation  
• Study terminated by Sponsor 
• Withdrawal by subject (only for discontinuing study drug , but will remain in study)  
The reason for subject discontinuation from study drug will be recorded in the electronic case 
report form (eCRF ). 
At the time of withdrawal from the study, the ET visit should be completed, as shown in the SoA 
(Table  1). 
If the subject  withdraws consent for disclosure of future information, the Sponsor may retain and 
continue to use any data collected before such a withdrawal of consent. 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 39 of 106 
 
 If a subject  withdraws from the study, he/she may request destruction of any samples taken and 
not tested, and the Investigator must document this in the site study records.  
5.3 Lost to follow up Procedure  
A subject  will be considered lost to follow -up if he or she repeatedly fails to return for scheduled 
visits and is unable to be contacted by the study sit e. 
The following actions must be taken if a subject fails to return to the clinic for a required study 
visit:  
• The site must attempt to contact the subject and reschedule the missed visit as soon as 
possible and counsel the subject on the importance of main taining the assigned visit 
schedule and ascertain whether or not the subject  wishes to and/or should continue in 
the study. 
• Before a subject  is deemed lost to follow up, the Investigator or designee must make 
every effort to regain contact with the subject (where possible, tele-health 
appointment and, if necessary, a certified or registered letter to the subject’s last 
known mailing address or local equivalent methods). All these contact attempts 
should be documented in the subject ’s medical record.  
• Should the subject continue to be unreachable, he/she will be considered to have 
withdrawn from the study.  
5.4 Screening Failure  
Screen ing failures are defined as subject s who consent to participate in the clinical study but are 
not subsequently entered in the study. Screen failure data  will be captured in EDC.  
Re-screening/re -assessment outside the screening period will b e possible on a case -by-case basis 
following Sponsor approval. Subject s allowed to be re -screened will be assigned a new screening 
number such subject s will be determined to be permanent screen failure s after the second screening 
determines a subject is ineligible.  
5.5 Classification of Subjects Who Discontinue the Study  
For any subject  who discontinues the study prior to completion, the most significant reason for 
early termination will be checked in the eCRF. Reasons are listed below from the most significant 
to the least significant:  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL  Page 40 of 106 Table 5: Discontinuation Reasons  
Adverse Event  To be used when the subject  is permanentl y terminated  from  the study  because 
of an AE (including  an SAE),  as define d in Secti on 9.1.1 
Lost to Follow -up To be used when  the subject  cannot  be found  or contacted  in spite  of efforts  to 
locate him/her before the date of his/her planned last visit, as outlined in Section  
5.3. 
Protocol Deviation  To be used in case of significant noncompliance with the protocol (e.g., deviation 
of the Inclusion/Exclusion criteria, non -compliance w ith time windows, blood 
sampling or vaccination refusal, missed injection/treatment, or error in the 
vaccine/treatment administration).  
Withdrawal by Subject  •When the subject  indicate s unwillingness to continue in the study
•When the subject  made the dec ision to discontinue participation in the
study for any personal reason other than an SAE/AE (e.g., subject  is
relocating, inform consent withdrawal, etc.)
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 41 of 106 
 
 6. TRIAL INTERV ENTION 
6.1 Investigational Product Description  
This study will investigate the safety and immunogenicity of bivalent GI.1 and GII.4 vaccine , 
administered orally  at total dose s of 1×1011 IU/dose  and 2×1011 IU/dose , for the prevention of NoV  
infection.  
• Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1 -/E3-Deleted Replication Defective 
Recombinant Adenovirus 5 with dsRNA Adjuvant (VXA-G1.1- NN) 
• Norovirus GII.4 Sydney VP1 Vaccine, Oral E1 -/E3-Deleted Replication Defective  
Recombinant Adenovirus 5 with dsRNA Adjuvant (VXA- GII.4 -NS) 
VXA -G1.1- NN and VXA -GII.4 -NS are E1/E3 -deleted, replication -incompetent, adenovirus 5 
vaccine vectors designed for use as vaccines for prevention of  NoV infection. The vaccine vectors 
encode for a full -length VP1 gene of either Norwalk virus (VXA -G1.1- NN vaccine) or Sydney 
virus (VXA -GII.4 -NS vaccine). In addition to the transgene cassette, a second hCMVie promoter 
is also present in the vaccine constructs which is used to express a ribonucleic acid (RNA) 
sequence that acts as an adjuvant. The adjuvant is a short hairpin RNA expressed off a promoter 
such that only target cells in the intestine that express antigen will also express the adjuvant. This 
is likely to result in a tight association of antigen with adjuvant in vivo. 
 
The VXA -G1.1- NN and VXA -GII.4 -NS vaccines are produced in tablet  form . The drug substance 
is formulated as compressed powdered solid material containing API, tromethamine, sucrose, 
arginine, hydrolyzed fish gelatin (type A), and polyvinyl pyrrolidone (PVP -grade K90). The 
formulated and  dried drug substance is blended with tableting excipients consisting of: 
microcrystalline cellulose, pre -gelatinized starch, magnesium stearate, and hydrophobic colloidal 
silica. All inactive ingredients incorporated into the drug product are generally re cognized as safe 
(GRAS) and all are included in currently approved, US -licensed oral drug products currently listed 
in the FDA Inactive Ingredients Database. The formulated drug substance is compressed into 
tablets and enteric coated with an acetone- based solution of methacrylate polymer and talc.  
The placebo for this study is manufactured similarly to the active Drug Product ( DP) tablets, but 
without the active drug substance. The placebo tablets are indistinguishable in appearance from 
the active DP table ts. The number of placebo tablets dispensed to the subject  will be matched to 
the active treatment groups. The placebo will be dispensed by the site’s in -house pharmacy in a 
manner indistinguishable from the active treatment groups.  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 42 of 106 
 
 6.2 Preparation and Dispensing of Investigational Product  
Investigational product  doses will be prepared at the study sites by an unblinded research 
pharmacist(s)  or designee  who will be provided treatment assignment through a randomization 
schedule.   
A trained member of the site study staff will dispense the tablet(s) constituting their assigned dose 
to the subject . 
See the Pharmacy  manual for instructions on how to prepare VXA-G1.1- NN and VXA -GII.4 -NS 
vaccines  and placebo  for administration.  
6.3 Dosing and Administration of Investigational Product  
This study will investigate the safety and immunogenicity of two monovalent NoV  oral tableted 
vaccine candidates (VXA -G1.1- NN and VXA -GII.4 -NS) co-administered (bivalent delivery) 
against a matching placebo arm. All lots of DP will be provided as small whi te enteric -coated 
tablets  for oral route of administration .   
Multiple tablets of study drug will be dispensed to allow delivery of the intended vaccine dose. A 
matching number of placebo tablets will be dispensed to maintain the study blinding. 
Table 6:  Investigational Product  Dosing 
Intervention 
Name VXA-G1.1-NN VXA-GII.4-NS Placebo 
Type Biologic  Biologic  Matching placeb o 
Dose 
Formulation  Enteric -coated tablets  Enteric -coated tablets  Enteric -coated tablets  
Dosing 
Schedule  Day 1  Day 1  Day 1  
Route of 
Administration  Oral 
Administration 
instructions  Subject s should fast and refrain from ingesting solid food for at least 4 hours prior to oral dosing. 
A trained member of the site study staff will dispense the tablet(s) constituting their assigned 
dose to the subject . The subject s will swallow the tablets with 360 to 480 mL of water or clear 
fruit juice (acidic, such as cranberry juice) followed by a light snack (e.g., crackers) at time of 
dosage administration to aid in tablet transit out of the stomach. Normal food consumption may 
resume 90 minutes after dosin g. For more information refer to the study specific  Pharmacy 
Manual.  
Sourcing  Study drug  will be provided to the sites by the Sponsor or designated representative.  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 43 of 106 
 
 Table 7: Study Arm(s)  
Arm Title * Open Label 
Sentinel Arm 1 Arm 2 Arm 3 
Arm Type  Experimental  Experimental  Experimental  Placebo  
Arm Description  Bivalent GII.4/GI.1 
vaccine  Bivalent GII.4/GI.1 
vaccine  Bivalent GII.4/GI.1 
vaccine  Placebo  
Per Strain Dose 
(IU) 1×1011 5×1010 1×1011 N/A 
Total Dose 
(IU/dose)  2×1011 1×1011 2×1011 N/A 
6.4 Formulation,  Appearance, Packaging , and Labelling 
Formulation : 
Both the VXA -G1.1- NN and VXA -GII.4 -NS are formulated as small enteric -coated tablets.  
Packaging and Labelling: 
The tablets are packaged into foil -sealed, high -density polyethylene (HDPE) screw -cap containers 
with 10 tablets per bottle.  
All packaging and labeling operations for study drug  will be performed according to Good 
Manufacturing Practices (GMP) for Medicinal Products and the relevant regulatory requirements. 
Label text for the study drug  bottle will at a minimum include name of the manufacturer, the 
protocol number, the name of the product, the lot number of the product, the concentration of the 
vaccine, the date of manufacturing or expiration.  
Secondary packagin g of the study drug  upon dispensing from the pharmacy to the clinical staff for 
subject dosing will be determined with consideration of the site ’ pharmacy standard operating 
procedures and outlined in the study pharmacy manual. 
The final subject  use dispensing container (cup or secondary bottle) will be appropriately labeled 
with specific requirements for the country and deemed necessary per the site’s standard operating 
procedures (i.e. subject randomization number , total tablet count, dispensin g date and time etc.)  
6.5 Product Storage and Stability 
Storage: 
The Investigator will be personally responsible for product management or will designate a study 
site staff to assume this responsibility.  
Both the VXA -G1.1- NN and VXA -GII.4 -NS DP should be stor ed at 2 -8 °C. The DP tablets may 
be kept at room temperature during the dispensation and administration process for a brief period. 
Please refer to the study specific Pharmacy Manual for detailed information.  
 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 44 of 106 
 
 Stability : 
Stability studies have been performed on similarly formulated tablets prepared from the same or 
similar adenovirus 5 constructs incorporating different antigens, including, VP1 Norwalk and other 
influenza antigens (e.g., hemagglutinin H1). The 2 -8°C data i ndicate that drug product potency 
will remain within release specification prior to retest.  Additionally, data from accelerated stability 
studies indicate that handling at controlled room temperature or brief exposure to temperatures 
above room temperatur e (below 37°C) is acceptable for this product. 
6.6 Accountability Procedures  
The Investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for study drug received and any discrepancies are reported and resolve d 
before use of study drug. 
Only subjects enrolled in the study may receive study drug  and only authorized site staff may 
supply or administer study drug . All bottles of study drug  must be stored in a secure, 
environmentally controlled, and monitored (manu al or automated) area in accordance with the 
labeled storage conditions with access limited to the Investigator and authorized site staff.  
The Investigator , institution, or the head of the medical institution (where applicable) is responsible 
for study dru g accountability, reconciliation, and record maintenance (i .e., receipt, reconciliation, 
and final disposition records). 
At the end of the study  active period , the unblinded monitor will conduct a final drug reconciliation 
for all subjects and the study si te overall. All records of study drug  administration, accountability 
records and study drug disposition records will be examined and reconciled by the study monitor. 
Further details will be provided in the study specific  Pharmacy Manual.  
Further guidance and information for the final disposition of unused study drug  are provided in 
the study specific Pharmacy Manual . 
6.7 Randomization and Blinding  
6.7.1 Randomization Procedure s 
Assignment of a Subject Number: 
Each subject  who sign s informed consent will be assigned a subject number. Only t he first 10 
sentine l subjects  will receive open label high dose of active vaccine (2×1011 IU). Following SMC 
recommendation  on review of sentinel safety data up to  and including Day 8 , new subjects once 
deemed eligible and enrolled in the study will also receive a randomization number and treatment 
assignment , based on the blinded randomization schedule . The subject  number will be used as the 
primary identifier for the complete duration of the study. After the subject  signs the informed 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 45 of 106 
 
 consent form (ICF), the Investigator (or designee)  will enter the subject  into the sites Screening 
Log. All screen failed  and randomized subjects will have data entered in the study specific EDC.  
After signing an informed consent, the subject s in the randomized double blind portion of the study 
will undergo screening assessments to determine study eligibility up to  45-day for Screening 
Period . All subjects who sign a study specific informed consent form will have data entered into 
the EDC. On Day  1, subject s will be randomized in a 2:2:1 ratio to one of the three treatment arms  
to receive  active vaccine  or placebo, as follows (Table 7). 
6.7.2 Blinding Procedure s 
The first 10 sentinel  subject s will be enrolled and receive the high dose of active vaccine in an 
open label  manner for a safety evaluation . 
If pre-established stopping rules are met, enrollment of subsequent s ubjects will be halted until the 
study SMC has completed the review of all available safety data and provides guidance regarding 
continuation of study. 
For remaining subjects , Investigator s, site personnel and the Sponsor (except as described below) 
will be blinded to individual subject  treatment assignment.  
Study drug  doses will be prepared at the study sites by an unblinded research pharmacist(s)  or 
designee who will be provided treatment a ssignment through a randomization schedule. 
Specifically designated Sponsor representative(s) will also have access to unblinded individual 
subject treatment assignments for the purposes of study -required activities, including management 
of study drug  inve ntory, production of summaries of data for SMC review, and performance of 
bioanalytical analysis. These personnel will not be directly involved in the conduct of the study. 
An SMC  may periodically convene to review unblinded overall safety as deemed necess ary to 
ensure the safety of study subject s (Section  10.2). 
Instructions for break ing the blind will be provided to the study site in case of a medical 
emergency. The Investigator has the sole responsibility for determining if unblinding of a subjec t’s 
treatment assignment is warranted. Subject safety must always be the first consideration in making 
such a determination. The Investigator must  notify the Sponsor’s Medical Monitor (or designee) 
prior to unblinding a subject ’s treatment assignment. The Investigator (s) must document and report 
to the Medical Monitor any breaking of the treatment code  but must not disclose the result of 
unblinding . The date and reason that the blind was broken must be recorded in the source 
documentation. 
Appropriate personnel at the Sponsor (or designee) will unblind suspected unexpected serious 
adverse reactions (SUSARs) for the purpose as required per each local regulation. The Sponsor 
will submit SUSARs to Regulatory Agencies in blinded or unblinded fashion according to  local 
law. The Sponsor will submit SUSARs to Investigators in a blinded fashion. 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL  Page 46 of 106 6.8 Treatment Compliance  
Subject s will receive study drug  directly from the Investigator or designee, under medical 
supervision. The date and time of each dose administered in the clinic will be recorded in the 
source documents  and recorded in the electronic case report form (eCRF ). The dose of study drug  
and study subject  identification will be confirmed at the time of dosing by a member of the study 
site staff other than the person administering the study drug.  
6.9 Overdose of Treatment  
Any overdose of intervention  should be recorded in the eCRF (including quantity of the excess 
dose and the duration of the overdose). AEs associated with an overdose or incorrect 
administration of study drug  should be recorded in the AE eCRF. An overdose will not be 
considered an SAE unless the outcome of the overdose meets seriousness criteria.  
The effects of acute overdose of VXA -G1.1- NN and VXA -GII.4 -NS in human are unknown. 
No spe cific antidote for overdose is known. Study subject s should be managed with appropriate 
supportive care if overdose occurs.  
6.10 Concomitant Medications and Other Therapies  
Concomitant medication is defined as any prescription or over-the- counter preparation . 
Use of concomitant medication from 4 weeks before Day  1 through Day 29 (completion of Active 
Study period) must be recorded onto the eCRF from the subject ’s medical file  along with:  
•Reason for use
•Dates of administration inclu ding start and end dates
•Dosage information including dose and frequency
Medications for pre-existi ng medical conditions or require d for a medical condition during the 
study are allowed if not considered exclusionary. 
The Sponsor's Medical Monitor (or designee) shoul d be contacte d if there are an y questions 
regarding concomitant or prior therapy. 
Prohibited Concomitant Medication: 
Medications specifically prohibited in the exclusion criteria are not allowed during the Active 
Study period ( Section 5.1 prior/concurrent therapy), unless deemed medically necessary by the 
Investigator.  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 47 of 106 
 
 7. SCHEDULE OF TRIAL PROCEDURES AND ASSESSMENTS  
7.1 Trial Procedures  
A schedule of trial procedures  and their timing are summarized in the S oA (Table  1). The day of 
the first investigational product vaccination is considered to be Day 1.  
7.1.1 Procedure to be followed on screening Day -45 to Day -1) 
Before enrollment and before any study- related procedures are performed, voluntary, written 
study- specific informed consent  will be obtained from the subject/ subject ’s legally Accepted 
Representative  (LAR) . Each signature on the IC F must be personally dated by the signatory. A 
copy of the  signed and dated IC F must be given to the subject . The source data must reflect that 
the informed consent was obtained before participation in the study. 
After obtaining signed copy of written informed consent from the subject  / subject ’s LAR , the 
subject will be undergone for screening procedure as mentioned below : 
• The demographic information  (i.e., age, ethnic origin, race, height (cm), body weight (kg), and 
body mass index (kg/m2) will be recorded:  
• Obtain history of drug abuse, alcohol abuse, and blood or plasma donation. 
• Obtain any medical history of clinical significance  and details of any medications currently 
taken . 
• Measure vital signs, including sitting blood pressure, pulse rate  and respiratory rate  after at 
least 5 minutes of rest to  the subject . 
• Measure subject ’s temperature (oral).Oral temperature is preferred for all visits. If unavailable, 
it is acceptable for clinical study sites to measure subject’s temperature according to site usual 
standard using tympanic thermometer instead of oral and this  should be clearly documented. 
All subjects must use the study -provided thermometer for daily oral temperature checks for 
solicited symptoms in the week following vaccine dose. 
• Perform physical examination evaluating any clinically significant abnormalities within the 
following body systems: general appearance; skin; head, eyes, ears, nose, and throat; 
cardiovascular ; pulmona ry; gastrointestinal (GI); musculoskeletal; extremities; neurological; 
and lymph nodes.  
• Perform a serum  pregnancy test for all female subject s at screening . At screening all women 
will have a negative serum HCG. Prior to dosing all women will have a negat ive urine HCG.  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 48 of 106 
 
 • Verify understanding of and compliance with protocol requirements for contraception  (see 
Appendix 4 ).  
• Ensure that all inclusion criteria are met and that none of exclusion criteria are met.  
• Obtain a urine sample for urine drug screen test . 
• Collect a blood sample to determine the subject ’s Human Immunodeficiency Virus ( HIV), 
Hepatitis B Virus ( HBV ), and Hepatitis C Virus ( HCV ) status.  
• Obtain COVID -19 vaccination status. 
• Complete the source documents.  
• The Investigator or an authorized designee completes the eCRFs . 
7.1.2 Procedure to be followed during Active Study Period (Day 1 to Day 29) 
It is anticipated that the procedures below will be conducted in a stepwise manner; ensur ing that 
procedures listed prior to administratio n of the vaccine are conducted prior to that administration 
for both the open label and randomized groups of the study. 
• The Principal Investigator will  ensure that all inclusion criteria and none of the exclusion 
criteria are met on Day1 , prior to vaccination. 
• A urine pregnancy test will be done for all female subject s prior to dosing. 
• A targeted, and symptom -directed physical examination  will be done for all subject s during 
the active study period visits. , At a minimum, assessments of the skin, respiratory system, 
cardiovascular system, and  GI (abdomen, liver and spleen) will be included . 
• Vital signs  will be obtained , including temperature, sitting blood pressure, pulse rate and 
respiratory rate after at least 5 minutes of rest to the subject  during the active study period. 
• The subject ’s number (open label) or randomization number will be noted .  
• Site staff member(s) will dispense/administer the investigational product. Please refer to the  
Pharmacy M anual for further instruction on this process.  
• Prior to study drug administration on Day 1,  the subject ’s temperature (oral)  will be 
measured , and a trained member of the site study staff will dispense the tablet(s) constituting  
the assigned dose to the subject. 
• For the subjects enrolled into the open label sentinel study arm, the site staff must observe 
the subjects at the site, in the ≥18 to ≤80 years old age group, for at least 2 hours after study 
drug administration for any acute reactions. Any acute r eactions are to be recorded in the 
subject’s source documents, on the AE page of the eCRF, and on a serious adverse event 
(SAE) form, as applicable.  
• For the subjects enrolled into the randomized double blind portion study arm, the site staff 
must observe the subjects  at the site,  in the ≥18 to ≤80 years old age group for at least 30 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL  Page 49 of 106 minutes after study drug administration for any acute reactions. Any acute reactions are to 
be recorded in the subject’s source documents, on the AE page of the eCRF, and on a serious 
adverse event (SAE) form, as applicable. Subjects will be asked to record symptoms of 
reactogenicity daily for 1 week after study drug administration on Day 1, using the Solicited 
Symptom Diary; the Solicited Symptom Diary will be collected from the subject on Day 8 
and reviewed.   
•Subjects will be queried for unsolicited AEs for 28 days following the study drug
administration and for SAEs,  AESIs and NOCIs for 1 year following the study drug
administration.
•Subjects will return t o the site (as specified in SOA) and a blood , nasal and saliva  sample s
will be collected for immunogenicity assessment.
•The subject will be asked to contac t the site staff or Investigator if an AE (e.g., doctor’s visit,
emergency room visit) or hospitalization occurs.
•The subject is to be informed that use of prophylactic antipyretic/pain medication, while
permitted, is not recommended on the day of study dr ug administration (before or after
vaccination). If prophylactic antipyretic/pain medication is used, and if clinically appropriate
in the judgement of the Investigator, acetaminophen is preferred over other non -steroidal
anti-inflammatory drugs.
•Prior and concomitant medications will be reviewed if the subjects took any during the active
study period.
•The subject will be asked to bring the completed Diary to the next visit.
•The subject will be reminded that study staff may contact them to obtain additional
information on events entered into the Solicited  Symptom Diary.
•Source documents will be completed.
•The Investigator or appropriately qualified designee  will review the Diary data online
following vaccination , to evaluate subject compliance and as part of the ongoing safety
review. Daily review is optimal during the active Diary period.  Any solicited symptom
marked as Grade 3 should be specifically reviewed with the subject to ensure they meet the
detailed solicited AE grading criteria  in (Table  11) and evaluate for potential alternative
etiology .
•An appointment will be scheduled for the subject  to return for the next study visit.
•The Investigator or an authorized designee completes the eCRFs and an unblinded
dispenser/administrator will update the investigational product accountability records.
7.1.3 Procedure to be followed during follow -up period  (Day 30 to Day 365) 
•Ensure that the subject meet s none of the withdrawal criteri a as described  in Section 5 .2. 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL  Page 50 of 106 •Verify understanding of and compliance with protocol requirements for contraception (see 
Appendix 4 ).
•Collect a blood sample for Immunogenicity a ssessment  as noted in the SoA (Table 1).
•Review  the subject’ s Diary data with the subject and collect the Di ary. Collec t stop dates  of 
any Diary events ongoing on the last day that the Diary was completed and record stop dates  
in the eCRF if required.
•Collect and record S AEs,  AESIs  and NOCIs .
•Complete the source documents.
•The Investigator or an authorized  design ee complet es the eCRFs.
•Ask the subject  to contac t the site staff or Investigator  if an adver se event  (e.g., doctor’s visit,  
emergency  room visit) or h ospitalization  occurs.
•The subjects  will be contacted  by phone  between  site visits  to monito r for safety  as specified  
in the SoA (Table 1). If the study personnel are unable to contact the subject with 3 attempts,  
the study personnel will follow instructions given in Section 5.3. 
Follow-up of subjects with Related AEs or with AEs that led to Study Discontinuation  
Unless the subject refuses further contact, each subject who experiences an AE (whether serious 
or non -serious) during the study must be followed until the condition resolves, becomes stable, or 
becomes chronic (even after the end of the subject ’s participation in the study) if either of the 
following is true . 
•The AE is considered by the Investigator to be related to the product administered.
• The AE caused the discontinuation of the subject  from the study.
7.1.4 Unscheduled Visit  
At the discretion of PI and/or per subject  request to evaluate any of the expected reactogenicity 
symptoms or any unexpected symptoms of concern , a contact must occur as soon as possible  
between  the subject  and the Investigator, or a medically qualified member of the study site staff, 
to assess if  an unscheduled visit is required. 
This contact will be recorded in the subject ’s eCRF. If the subject  is unable to attend the 
unscheduled visit, any ongoing reactions must be assessed at the next scheduled visit. 
Reactogenicity events should be assessed b y the Investigator or a medically qualified member of 
the site staff , such as a study physician or a study nurse, as applicable , to the Investigator’s local 
practice, who will:  
•Measure oral temperature.
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 51 of 106 
 
 • Measure the subject ’s pulse rate  (after five minutes of sitting) . 
• Measure the subject ’s blood pressure ( after five minutes of sitting).  
• Assess any systemic events (specify the events of interest) that are present , in accordance with 
the reactogenicity grading scale . 
• Ask the subject  if he/she attended an emergency room visit or was hospitalized.  
• Complete the source documents.  
• The Investigator or an authorized designee will complete the eCRF. 
The subject  will be instructed to contact the site to report any significant illness, AE s, or 
hospitalization that occurs during the study period. 
7.2 Management of Blood / Saliva / Nasal Samples 
7.2.1 Blood / Saliva/Nasal S ample Collection 
Blood / saliva /nasal  samples for the assessment of immunogenicity will be collected from the 
subject s as specified in the S oA (Table  1). Sample collection, storage, and shipping information 
can be found in the study specific Laboratory Manuals. 
7.2.2 Blood/ Saliva/Nasal  Sample Preparation 
Detailed instructions on how to prepare blood samples for assessment of immune response are 
contained in the study specific Laboratory Manual provided to the site.  
7.2.3 Blood/ Saliva/Nasal  Sample Storage and Shipment  
Detailed instructions on blood sample storage and shipment are c ontained in the study specific  
Laboratory  Manual provided to the site.  
7.2.4 Future use of stored specimens and data  
The current trial is an early phase study  in which Vaxart’s  goal is to understand the mechanism of 
action of the oral NoV  vaccine in the prevention of NoV  illness, it is important to have samples 
available for the full characterization of the vaccine. The Sponsor is planning to store  blood, saliva 
and nasal  sample s post the completion of the study for possible future testing towards the 
development of a NoV  vaccine.  This testing includes evaluation of serum antibody titers to NoV  
and cell -mediated immune responses to NoV . At this time, the exact tests are not known  but this 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 52 of 106 
 
 will help to further understand how the oral NoV  vaccine works in the body and in the prevention 
of NoV  illness.  Other immunological assays may be performed to further elucidate the response 
to our vaccine.  These may include cloning the antibodies that are induced following immunization. 
All samples will use subject identifiers that are coded and will not include subject initials or 
demographic information. Only Vaxart staff will  have access to the samples and data; they will be 
responsible for pr oviding access to the samples as needed for assays. Samples will be stored at 
Vaxart or Vaxart’s designee in a secured, access -controlled location  for at least 05 years  after the 
last license approval in the relevant market areas has been obtained for the vaccine being tested.  
Samples may be shared with collaborating researchers, but only in relationship to the NoV  
program. Any data developed externally will only be displayed in a deidentified form as authorized 
by Vaxart.   
8. TRIAL ASSESSMENT S AND PROCEDU RES 
Study procedures and their timing are summarized in the SoA (Table  1). Protocol waivers or 
exemptions are not allowed.  
Immediate safety concerns should be discussed with the Sponsor immediately upon occurrence or 
awareness to determine if the subject  should continue or discontinue study drug. 
Adherence to the study design requirements, including those specified in the SoA  is essential and 
required for study conduct. 
All screening evaluations must be completed and reviewed to confirm that pot ential subject s meet 
all eligibility criteria. The Investigator  will maintain a screening log to record details of all subject s 
screene d and to confirm eligibility or record reasons for screening failure, as applicable.  
Subject s who experience any serious or severe TEAEs, or any event of concern should be 
instructed to contact the study site and be scheduled for a visit for further evalua tion. If an 
unscheduled visit occurs, the reason for the visit and data collected during the visit should be 
recorded and entered into the unscheduled eCRF. 
8.1 Safety Assessment  
The safety of the bivalent GI .1 and GII.4 vaccines  will be evaluated through the reporting of 
Solicited Symptoms of Reactogenicity (GI and systemic) for 1 week following the study drug  dose 
and through reporting of frequency, duration, and severity of unsolicited  AEs for the next 28 days 
following the study drug  dose. The subject s will then enter the Follow -Up P eriod after Day 29 and 
will be monitored for SAEs,  AESIs, and NOCIs through Day 365 ( Month 12 ) for safety and 
duration of immune response. 
AESIs are listed in  Appendix 5 , the occurrence of these events should be reported to the Sponsor 
in an expedited manner, similar to SAEs as described in Section  9.  
Planned time points for all safety assessments are provided in the SoA  (Table  1). 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 53 of 106 
 
 8.1.1 Physical Examination  
A complete  physical examination evaluating any clinically significant abnormalities  in general 
appearance and  within the following body systems: skin; head, eyes, ears, nose, and throat; 
cardiovascular; pulmonary; gastrointestinal (GI) (abdomen; liver and spleen)  musculoskeletal; 
extremities; neurological; and lymph nodes.  Height and weight will also be measured and recorded 
at screening  and BMI will be calculated . 
A targeted, symptom -directed  physical examination will include, at a minimum, assessments of 
the skin, respiratory system , cardiovascular system, and GI (abdomen, liver and spleen ). 
8.1.2 Vital Signs  
Blood pr essure, heart rate, and respiratory rate will be measured after the subject has been resting 
for 5 minutes. Vital signs will be measured prior to any blood draw that occurs at the same 
timepoint.  
8.1.3 Clinical Safety Laboratory Tests 
• See Appendix 1  for the list of clinical laboratory tests to be performed for inclusion and 
exclusion purposes only. 
8.1.4 Pregnancy Testing  
• Details of all pregnancies in female subjects, will be tested as outlined in SoA (Table  1). 
• If a pregnancy is reported, the Investigator  should inform the Sponsor within 24 hours of 
learning of the pregnancy and should follow the procedures outlined in Section 9.1.8 . 
8.2 Immunogenicity Assessments  
Immunogenicity will be evaluated using cellular and humoral immune function assays from blood 
and mucosal (saliva and nasal swab) samples. Samples will be collected from all subjects 
according to the time points specified in the SoA. The following analytes will be measured:  
Primary Immunogenicity Assessments:  
• Serum –Anti IgA for both GI.1 and GII.4 by Meso Scale Discovery (MSD) assay by 
dose level 
o geometric mean concentration (GMC) at Day 1 and Day 29 
o geometric mean fold rise (GMFR) from Day 1 to Day 29  
 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 54 of 106 
 
 • Serum -Antibody titers for both GI.1 and GII.4 by Histo -blood group antigen (HBGA) -
Blocking Assay (BT50) –  
o geometric mean titer (GMT) Day 1 and Day 29  
o  geometric mean fold rise (GMFR) from Day 1 to Day 29  
 
• Serum Anti- IgG for both GI.1 and GII.4 by MSD a ssay  
o geometric mean concentration (GMC) at Day 1 and Day 29  
o geometric mean fold rise (GMFR) from Day 1 to Day 29  
Exploratory Immunogenicity Assessments:  
• Serum - Anti-VP1 GI.1 IgA and Anti -VP1 GII.4 IgA  by Meso  Scale Discovery (MSD) 
assay by dose level 
o geometric mean concentration (GMC) at Day 8 and Day 180 
o geometric mean fold rise (GMFR) from Day 1 to Day 8 and from Day 1 to Day 
180 
 
• Serum - Anti-VP1 GI.1 IgG and Anti -VP1 GII.4 IgG  by Meso Scale Discovery (MSD)  
assay by dose level 
o geometric mean concentration (GMC) at Day 8 and Day 180 
o geometric mean fold rise (GMFR) from Day 1 to Day 8 and from Day 1 to Day 
180 
 
• Serum - Antibody BT50 titers for both GI.1 and GII.4  by Histo -blood group antigen 
(HBGA) Assay    
o geometric mean titer (GMT) Day 8 and Day 180  
o geometric mean fold rise (GMFR) from Day 1 to Day 8 and from Day 1 to Day 
180 
 
• Nasal Swab – Anti-VP1 GI.1 IgA and Anti-VP1 GII.4 IgA 
o geometric mean concentration (GMC) at Day 1, Day 8, Day 29 and Day 180 
o geometric mean fold rise (GMFR) from Day 1 to Day 8, Day 1 to Day 29 and 
from Day 1 to Day 180 
 
• Saliva – Anti-VP1 GI.1 IgA and Anti-VP1 GII.4 IgA 
o geometric mean concentration (GMC) at D ay 1, Day 8, Day 29 and Day 180 
o geometric mean fold rise (GMFR) from Day 1 to Day 8, Day 1 to Day 29 and 
from Day 1 to Day 180 
 
 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 55 of 106 
 
 • Fixed Whole Blood (required for blood draw, optional for testing)  
o B-cell immunophenotyping at Day 1 and Day 8   
Additional exploratory immunogenicity assays may also be performed to further evaluate the 
activity of the bivalent GI.1 and GII.4 vaccines. Note that not all sample timepoints may be 
relevant for some of the analysis, so not all assays may be performed at  all timepoints.  
Sample collection, processing and shipping details are provided within the study specific  
Laboratory Manual . 
9. ADVERSE EVENTS  
9.1.1 Definition of an Adverse Event, Serious Adverse Event, Adverse Event of Special 
Interest, New Onset of Chronic Illness , and Unanticipated problems  
Adverse Event  
Adverse event means any untoward medical occurrence associated with the use of an intervention 
in humans, whether or not considered intervention related. 
Serious Adverse Event  
An adverse event (AE) or suspected adverse reaction is considered "serious" if, in the view of 
either the Investigator or S ponsor, it results in any of the following outcomes: death, a life -
threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a 
persistent or significant incapacity or substantial disruption of the ability to conduct normal life 
functions, or a congenital anomaly/birth defect. Important medical events that may not result in 
death, be l ife-threatening, or require hospitalization may be considered serious when, based upon 
appropriate medical judgment, they may jeopardize the subject  and may require medical or 
surgical intervention to prevent one of the outcomes listed in this definition.  
Note: Hospitalization for elective treatment of a pre -existing condition that did not worsen from 
baseline is not considered an AE/S AE. 
Adverse Event of Special Interest  
An adverse event of special interest (serious or nonserious) is one of scientific and medical concern 
specific to the Sponsor’s product or program, for which ongoing monitoring and rapid 
communication by the Investigator to the Sponsor can be appropriate.  For this study,  AESI s are 
serious or non -serious adverse event s of scientific and medical concern with potential immune -
mediated medical conditions as well as events associated with thrombosis and thrombocytopenia  
as listed in  Table 12. 
 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 56 of 106 
 
 New Onset of Chronic Illness  
New Onset of Chronic Illness  is defined as diagnosis post -enrollment and vaccination of a new 
medical condition which is chronic in nature, including those potentially controllable by 
medication (e.g.,  diabetes, asthma).  Adverse ev ents of special interest  and NOCIs will be collected 
and reported for all participants from the moment of first study drug administration until the end 
of the Safety -Follow-up Period through Day 365. 
Unanticipated problems  
The Office for Human Research Protections (OHRP) considers unanticipated problems involving 
risks to subject s or others to include, in general, any incident, experience, or outcome that meets 
all of the following criteria:  
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures 
that are described in the protocol -related documents,  such as the Institutional Review 
Board (IRB) -approved research protocol and informed consent document; and (b) the 
characteristics of the subject  population being studied; 
• Related or possibly related to participation in the research (“possibly related” me ans 
there is a reasonable possibility that the incident, experience, or outcome may have 
been caused by the procedures involved in the research); and 
• Suggests that the research places subject s or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or 
recognized. 
Adverse Reaction:  
All noxious and unintended responses to a medicinal product related to any dose should be 
considered adverse reactions (AR).  
(The phrase “responses to a medicinal  product” means that a causal relationship between a 
medicinal product and an AE is at least a reasonable possibility.) 
The following additional definitions are being used by the Sponsor.  
Solicited Adverse E vents: 
Solicited adverse events ( AEs) are predefined signs and symptoms of reactogenicity for which the 
subject is specifically questioned, and which are noted by the subject  in their Solicited Symptom 
Diary, including: 
• fever (any temperature 100°F or higher) 
• headache  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 57 of 106 
 
 • myalgia (muscle pain)  
• abdominal pain  
• anorexia (defined and not eating) 
• nausea  
• vomiting 
• diarrhoea  
• malaise/fatigue  
Subjects will utilize a Solicited Symptom Diary issued on the day of the vaccination to record 
solicited any TEAE daily for the one week following that administration.  
Unsolicited AE:  
An unsolicited AE is an observed AE that does not fulfill the conditions prelisted in the eCRF in 
terms of diagnosis and/or onset window post -vaccination. Unsolicited AEs includes both serious 
(SAEs) and non- serious unsolicited AE.  
Sentinel subjects will be kept at the site under observation for 2 hours after vaccination to ensure 
their safet y. If there are no safety concerns during this period then randomized subjects  will be 
kept under observation for 30 minutes  after vaccination to ensure their safety. The post -vaccination 
observation period should be documented (including the actual time of observation) in the source 
document.  
9.1.2 Grading of Severity of an Adverse Event  
For adverse events (AEs) not included in the protocol defined grading system, the following 
guidelines will be used to describe severity : 
• Mild – Events require minimal or no treatment and do not interfere with the 
subject ’s daily activities.  
• Moderate – Events result in a low level of inconvenience or concern with the 
therapeutic measures. Moderate events may cause some interference with 
functioning. 
• Severe – Events interrupt a subject ’s usual daily activity and may require systemic 
drug therapy or other treatment. Severe events are usually potentially life -
threatening or incapacitating. Of note, the term “severe” does not necessarily equate 
to “serious”. 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 58 of 106 
 
 9.1.3 Relationship of Adverse Event Following Immunization to Experimental  Vaccine 
/Vaccine Adverse Event  Causality Assessment  
There are five principles that underpin the causality assessment for vaccine adverse events:  
1. Biological plausibility  
2. Temporal relation  
3. Consistency  
4. Specificity  
5. Strength of association  
For more details, refer to the causality assessment of an adverse event following immunization 
(AEFI ): user manual for the revised who classification second edition, 2019 update link 
https://www.who.int/publications/i/item/9789241516990 
All adverse events  following immunization  (AEFIs ) must have their relationship to study drug  
assessed by the  Investigator  (clinician who examines and evaluates the subject  based on temporal 
relationship and his/her clinical judgment ). The degree of certainty about causality will be graded 
using the categories below. In a clinical trial, the study product must always be suspect.  
• Definitely Related – There is clear evidence to suggest a causal relationship, and other 
possible contributing factors can be ruled out. The clinical event, including an abnormal 
laboratory test result, occurs in a plausible time relationship to study drug  administration 
and cannot be explained by concurrent disease or other drugs or chemicals. The response 
to withdrawal of the study drug should be clinically plausible.  
• Probably Related – There is evidence to suggest a causal relationship, and the influence 
of other factors is unlikely. The clinical event, including an abnormal laboratory test 
result, occurs within a reasonable time after administration of the study drug, is unlikely 
to be attributed to concurrent disease or other drugs or chemicals, and follows a clinically 
reasonable response on withdrawal . 
• Potentially Related – There is some evidence to suggest a causal relationship (e.g., the 
event occurred within a reasonable time after administration of the trial medication). 
However, other factors may have contributed to the event (e.g., the subject ’s clinical 
condition, other concomitant events). Although an AE may rate only as “possibly related” 
soon after discovery, it can be flagged as requiring more information and later be 
upgraded to “probably related” or “definitely related”, as appropriate. 
• Unlikely to be related – A clinical event, including an abnormal laboratory test result, 
whose temporal relationship to study drug  administration makes a causal relationship 
improbable (e.g., the event did not occur within a reasonable time after administr ation of 
the study drug) and in which other drugs or chemicals or underlying disease provides 
plausible explanations (e.g., the subject ’s clinical condition, other concomitant 
treatments).  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 59 of 106 
 
 • Not Related – The AE is completely independent of study drug admini stration, and/or 
evidence exists that the event is definitely related to another etiology. There must be an 
alternative, definitive etiology documented by the clinician. 
9.1.4 Monitoring of Adverse Events during Trial  
9.1.4.1 Monitoring of AE/SAEs from Day 1 to Day 29 after vaccination  
Following AEs/SAEs, could appear during the entire course of the trial after vaccination . The 
following symptoms will be captured via Solicited Symptoms during Day  1 to Day  8. After 
Day 8 they will be captured as unsolicited adverse events. SAEs are captured from the first dose 
of study product.  
• Fever/pyrexia 
• Diarrhea  
• Nausea  
• Vomiting  
• Abdominal pain  
• Malaise/ fatigue  
• Anorexia 
• Headache  
• Myalgia (muscle pain)  
9.1.5 Time Period and Frequency for Collecting AE, AESI, NOCIs, and SAE 
Information  
All AEs AESIs  and NOCIs  will be collected from the first dose of study product  until the follow -up 
visit at the timepoints specified in the SoA (Table  1). 
Medical occurrences that begin before the start of study drug  but after obtaining informed consent 
will be recorded as medical history/current medical conditions, not as AEs  if it does not have a 
causal relationship with study participation .  There are two situations to note as below. 
1. If the medical occurrence causes the subject to be excluded from the study, then it must be 
reported by the investigator. This event will then need to be classified as an "AE not related 
to the study drug.”   
2. If the medical occurrence is the result of a protocol -specified intervention  (prior to study 
drug dose), including but not limited to washout or discontinuation of usual therapy, diet, 
or a procedure  then these must be reported appropriately as an AE (solicited and 
unsolicited), SAE, AESI, NOCI , and other reportable safety events by the Investigator. 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL  Page 60 of 106 All SAEs  will be recorded and reported to the  Sponsor  or designee  immediately  and under  no 
circumstance  should  this exceed  24 hours  of being  available.  The Investigator  will submit  any 
updated SAE data to the Sponsor within 24 hours of it being available. 
Investigators  are not obligated to  actively  seek information on  AEs or SAEs  after conclusion  of 
the study participation. However, if the Investigator  learns of any SAE, including a death, at any 
time after a subject has been discharged from the study, and the Investigator considers the event 
to be reasonably  related to  the study drug or  study  participation,  the Investigator must  promptly 
notify the Sponsor. 
9.1.6 Follow-up of AEs, AESIs, NOCIs and SAEs 
After the initial AE/SAE report, the Investigator is required to proactively follow each subject at 
subsequent visits/contacts. All SAEs will be followed until resolution, stabilization, the event 
is otherwise explained, or the subject i s lost to follow -up (as defined in Section 5.3).  
The Investigator is obligated to perform or arrange for the conduct of supplemental measurements 
and evaluations as  medically  indicated to e lucidate  the nature  and causality  of the AE, AESIs , 
NOCIs  or SAE s as fully  as possible.  This may include  laboratory tests  or investigations, 
histopathological examinations, or consultation with other h ealth care professionals . 
New or upda ted information will be recorded in the originally submitted documents. 
The Investigator will submit a ny update d SAE data t o the Sponsor within 24 hours of receipt of 
the information  
9.1.7 Reporting of Adverse Event, Adverse Event of Special Interest, New Onset of 
Chronic Illness, Serious  Adverse Events and Unanticipated problems  
All AEs (solicited and unsolicited), AESIs, NOCIs SAEs and other reportable safety events that 
occur after the co nsent form is signed but before study product administration must be reported by 
the Investigator if the event cause the subject to be excluded from the study (these will be report ed 
as “AE not related to  the study drug”) or is the result of a protocol -specified intervention, including 
but not limited to washout or discontinuation of usual therapy, diet, or a procedure. 
Table 8 below summarizes the different reporting timelines for TEAEs (unsolicited and solicited), 
AESIs , NOCIs, SAEs, and SUSAR.  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 61 of 106 
 
 Table 8 Adverse Event Reporting Timelines to t he Sponsor  
Type of 
Event TEAE 
(unsolicited)  TEAE (solicited)  AESI/NOCIs SAE / SUSAR  
Reporting 
period From first dose 
until 4 weeks after 
last dose of study 
drug 1 week after each 
study drug 
administration  From first dose 
until EOS  From first dose 
until EOS  
Reporting 
Timelines 
to the 
Sponsor  Entered into the 
clinical database 
on an ongoing 
basis  Entered into the 
clinical database 
on an ongoing 
basis  Within 24 hours  Within 24 hours  
Reporting 
Method AE page of  eCRF  Solicited 
Symptom Diary  AE page of  eCRF  AE page of  eCRF  
Abbreviations: AE = adverse event; eCRF = electronic Case Report Form; EOS = end of study; AESI = Adverse 
Event of Special Interest; NOCI=  New Onset Chronic Illness; SAE = serious adverse event; SUSAR = suspected 
unexpected serious adverse reaction; TEAE = treatment -emergent adverse event  
Adverse Event Reporting  
All subject s experiencing AEs after the first dose of study drug , until D ay 29 (Active Period), 
whether considered causally related with the use of the investigational vaccine or not , must be 
monitored until symptoms subside, or until there is a satisfactory explanation for the changes 
observed, or until death, in which case a full pathologist’s report should be supplied, if possible. 
All findings must be reported on an adverse event page of eCRF and on the SAE form, if 
applicable. All findings in subjects experiencing AEs must also be documented in the subject ’s 
clinical research  records.  
The following information will be documented for each event:  
• Reported term for the AE.  
• Start and end date.  
• Serious (Y/N)? If yes, appropriate seriousness criteria must be selected on eCRF and SAE 
Form.  
• Severity.  
• Investigator’s opinion of the causality (relationship) between the event and administration 
of investigational vaccine(s) (“related” or “not related”).  
• Investigator’s opinion of the causality (relationship) to trial procedure(s), including the 
details of the suspected procedure.  
• Action taken w ith study treatment (investigational vaccine) .,  
• Outcome of event.  
• For Death cases provide all applicable details (e.g. date and cause  of death etc , including 
autopsy results if available).  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 62 of 106 
 
 Serious Adverse Events Reporting  
The Investigator  or designee  will immediately report to the Sponsor any serious adverse event, 
whether or not considered study drug  related, including those listed in the protocol or Investigator 
Brochure and must include an assessment of whether there is a reasonable pos sibility that the study 
drug caused the event. Study endpoints that are serious adverse events (e.g., all -cause mortality) 
must be reported in accordance with the protocol unless there is evidence suggesting a causal 
relationship between the study drug  and the event (e.g., death from anaphylaxis). In that case, the 
Investigator must immediately report the event to the Sponsor. 
All SAEs will be followed until satisfactory resolution or until the site Investigator  deems the event 
to be chronic or the subject  is stable. Other supporting documentation of the event may be 
requested by the Data Coordinating Center (DCC)/study Sponsor and should be provided as soon 
as possible.  
The study Sponsor will be responsible for notifying the Food and Drug Administration (FDA of 
any unexpected fatal or life -threatening suspected adverse reaction as soon as possible, but in no 
case later than 7 calendar days after the Sponsor's initial receipt of the information. In addition, the 
Sponsor must notify FDA and all participating Investigator s in an Investigational New Drug (IND 
safety report of potential serious risks, from clinical trials or any other source, as soon as possible, 
but in no case later than  15 calendar days after the Sponsor determines that the information 
qualifies for reporting.  
All SAEs will be recorded and reported to the Sponsor or designee immediately and under no 
circumstance should this exceed 24 hours. The Investigator will submit any updated SAE data to 
the Sponsor within 24 hours of it being available. 
9.1.8 Pregnancy  
Details of all pregnancies in female subject s will be collected after the start of study drug as per 
SoA (Table  1).  
• If a pregnancy is reported, the Investigator will record pregnancy information on the 
appropriate form (pregnancy form) and submit it to  the Sponsor within 24 hours of 
learning of the female subject  or female partner of male subject (after obtaining the 
necessary signed informed consent from the female partner) pregnancy. 
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elect ive termination of a pregnancy for medical reasons will be 
reported as an AE or SAE. 
• Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs and will be reported 
as such.  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 63 of 106 
 
 • The subject /pregnant female partner  will be followed to determine the outcome of the 
pregnancy. If the  subject /pregnant female partner  (after consent is obtained to follow 
the pregnancy) delivers an  infant, the subject/pregnant female partner  and the infan t 
will be followed up to one month post-delivery. The Investigator will collect follow -
up information on the subject /pregnant female partner  and the neonate and the 
information will be forwarded to the Sponsor. 
• Any post study pregnancy- related SAE considered reasonably related to the study 
drug by the Investigator will be reported to the Sponsor. While the Investigator is not 
obligated to actively seek this information in former (study subject s/pregnant female 
partner) beyond the resolution of the pregnancy, he or she may learn of an SAE 
through spontaneous reporting. 
• Any female subject who becomes pregnant while participating in the study will 
discontinue study drug or be withdrawn from the study  may request continuati on of 
study drug. 
Should a female subject  become pregnant during the course of the study  after dosing, she will 
continue to be followed for safety  and pregnancy outcomes. Subject s who have a positive 
pregnancy test at Day 1, prior to randomization, will be considered screen failures. 
If a subject is found pregnant post study drug administration, the subject will only be mo nitored 
for safety.   
Death Events  
Events resulting in death will be an SAE regardless of association to study drug . Death is an 
outcome and should not be reported as an event term. The event that leads to the death should be 
reported as the SAE term.  
10. Safety Oversight  
10.1 Internal Sponsor Review  
Safety data will be monitored on an ongoing basis by the Investigator (or medically qualified 
designee) and the Sponsor’s Medical Monitor (or designee) in order to promptly identify and flag 
any event that potentially contributes to a Stopping Rule. 
The le ad Medical Monitor will be a physician experienced in the conduct of research clinical 
studies whose primary responsibility will be to monitor subject  safety. The Medical Monitor will 
be responsible for reviewing the cumulative safety data, including a review of safety laboratory 
test results and adverse event reporting. The Medical Monitor will be  familiar with study -specific 
data as well as relevant background information about the disease, investigational drug, and target 
population under study. The Med ical Monitor(s) will be empowered to request a SMC safety 
review which can suspend the study, recommend amendments to the protocol, and/or to request 
further information.  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL  Page 64 of 106 10.2 Safety Monitoring  Committee  
The first 10 sentinel  subjects  will receive  open  label  high dose of  active vaccine (2×1011) in a 
staggered manner, no more than two (2) subjects dosed in a 24-hour period. All subjects dosed 
will be observed for a  minimum of 2 hours post dose. While ten (10) subjects will be dosed in 
the sentinel group, to allow for dropouts, eight (8) subjects with complete safety data (defined as 
Day 1 to Day 8) will be enough to convene the SMC.  If no dose-related toxicities are observed, 
and upon consideration of the SMC recommendations following review of safety data, 
enrollme nt of the randomized double-blind study  w ill be initiated. 
Alternatively , if pre-established stopping rules are met, enrollment of subsequent subjects will be 
halted until the study SMC has completed a review  of all available  safety  data and offers 
a reco mmendation to proceed. 
If any of the events described below are met during the overall conduct of the study (open label 
and randomized phase), the study will be halted, and no new randomization/vaccinations will be 
allowed pending an S MC safety review 
•One or more subjects experiences a treatment -related serious adverse event (SAE) of any
grade
•Two or more subjects experience the same treatment -related grade ≥3 solicited  symptom
within one week following vaccination.
•Two or more subjects experience the same treatment -related unsolicited grade ≥3 AE
between Day 1 and Day 29 (A ctive Period).
The SMC will provide study oversight throughout the duration of the trial active and safety 
follow -up periods (Day 1 through Day 365 post-vaccination).  
The IRB, US FDA -CBER will be notified if the study is halted for safety concerns . 
A SMC will be created  to provide oversight of the conduct of the trial to ensure the safety of 
subject s and the validity and integrity of study data . The committee will consist of independent 
physicians and/or scientists with vaccine clinical trials experience  or expertise , and the Medical 
Monitor , who does not enroll subject s into the study.  Please refer to the study specific SMC for 
details.   
The SMC will function in accordance with the following provisions: (1) United States (US) Code 
of Federal Regulations  (CFR) applicable to clinical studies (21 CFR Part 50, 21 CFR Part 54, 21 
CFR Part 312.55 and 312.56. (2) ICH E6 and 62 Federal Register 25691 (1997):  Good Clinical 
Practice (GCP)  Consolidated Guideline. 
Further details of the composition, pre -specified me etings and objectives of the SMC will be 
outlined in the SMC Charter.  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 65 of 106 
 
 11. STATISTICAL CONSIDERATION  
A formal Statistical Analysis Plan (SAP) will be developed and finalized prior to locking the 
database. The full details of data presentation and analyses will be provided in SAP. 
Additional statistical analyses other than these  described in this section may be performed if 
deemed appropriate and included in the SAP. Any deviations from the final SAP or from what is 
outlined in the protocol will be discussed in the final study report (CSR).  
11.1 Hypothesis  
No hypothesis testing is planned for this study. 
11.2 Sample Size Determination  
A sample size of 125 randomized subjects (50 each in medium and high dose levels and 25 in 
placebo) in addition to 10 sentinel subjects is not based on formal statistical testing but rather based 
on clinical judgement and predicted to yield meaningfu l safety and immunogenicity results. 
Placebo was added for safety comparison. 
11.3 Multiplicity Adjustment  
No multiplicity adjustment will be implemented for this study . 
11.4  Population for Analysis 
For purposes of analysis, the following analysis sets are defined: 
Table 9: Populations for Analyses 
Analysis 
Population  Description  
Screened  All subjects who enter screening (assigned a screening number) 
Intent to Treat (ITT)  All subject s who are randomized. The an alyses using ITT will be based 
upon the randomization group allocated. 
Per Protocol  All subjects in the ITT set who receive one dose and  who have not 
violated any inclusion/exclusion criteria and / o r deviated in a way that 
could influence their Immunogeni city assessments . 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 66 of 106 
 
 Analysis 
Population  Description  
Safety  All random ized subject s who receive at least 1 dose of the study drug . 
Subject s will be analyzed according to the treatment (vaccine) they 
actually received . All safety analyses will be conducted based on the 
Safety set. 
Immunogenicity  All random ized subject s who receive at least 1 dose of the study drug  
and have at least one valid immunogenicity result after Day 1 . Subject s 
will be analyzed according to the treatment (vaccine) they actually 
received. All immunogenicity analyses will be conducted based on the 
Immunogenicity  set. 
11.5 Statistical Analysis  Plan 
11.5.1 General Approach  
The SAP will be developed and finalized before database lock and breaking the blind for any of 
the planned analyses. It will describe the subject sets to be included in the analyses and the 
procedures for accounting for missing, unused, and spurious data. This section provides a 
summary of the planned statistical analyses of the primary endpoints.  
11.5.2 Analysis of the Primary Safety  End Points  
Safety will be summarized for the safety  set (active vs. placebo). Solicited Symptoms of 
Reactogenicity, unsolicited AEs, SAEs, physical examination, and vital signs will be summarized 
descriptively by treatment group and study visit. 
Analyses will be performed for the total set (active vs. placebo). 
Endpoint  Statistical Analysis Methods  
Primary  
(measured 
from Day  1 
through Day 
29) Frequency, duration, and severity of Solicited Symptoms of Reactogenicity 
(local, systemic) measured daily for 1 week following vaccination. 
Frequency, duration, and severity of unsolicited AEs, and SAEs through the 
active period (4 weeks post last dose) . 
Descriptive statistics will be provided for each reactogenicity endpoint for each 
dose. Loca l reactions and systemic events from Day  1 through Day 8 after each 
dose will be presented by severity and cumulatively across severity levels. 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 67 of 106 
 
 Descriptive summary statistics will include counts and percentages of subject s 
with the indicated endpoint and t he associated Clopper -Pearson 95% CIs. 
AEs will be categorized according to the Medical Dictionary for Regulatory 
Activities (MedDRA®) terms. Descriptive summary statistics (counts, 
percentages, and associated Clopper -Pearson 95% CIs) will be provided for 
any TEAEs for each vaccine group as well as the placebo group. SAEs will be 
categorized according to MedDRA® terms. The safety analyses are based on 
the safety set. Subject s will be summarized by vaccine group and placebo 
according to the study drug  they actually received. Missing reactogenicity 
Diary data will not be imputed; missing TEAE dates will be handled according 
to the rules determined in the SAP.  
Exploratory 
(measured 
from Day 30 
through Day 
365) Frequency, duration, and severity of SAEs, AESIs and NOCIs for 1 year 
following the study drug dose. 
11.5.3 Analysis of Primary  and Exploratory Immunogenicity  End Points  
Immunogenicity will be summarized according to the treatment group to which the subject  was 
randomized. 
Immunogenicity samples will be drawn for all subject s. Immunogenicity analyses will be based 
upon results from appropriately sized subsets of samples, according to the purpose. The 
statistical analysis of immunogenicity results will be primarily based on the evaluable 
immunogenicity sets. An additional analysis will be performed based on the all -available sets if 
there is a large enough difference in samp le size between the all -available immunogenicity set 
and the evaluable immunogenicity set.  
Immunogenicity will be summarized by the total set (active vs. placebo).  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 68 of 106 
 
 Endpoint  Statistical Analysis Methods  
Primary  (Key 
Immunogenicity 
Endpoints) All measures will be analyzed comparing the two active vaccine groups. 
The immunogenicity set will be used for this  analysi s. All results will be 
presented descriptively and summarized by treatment groups.  
.For specific primary immunogenicity endpoints please refer to Section 8.2-
Immunogenicity Assessments - Primary Immunogenicity Assessments:  
Exploratory All measures will be analyzed comparing the two active vaccine groups. 
The immunogenicity set will be used for this analysis. All results will be 
presented descriptively and summarized by treatment groups. The analysis 
of these bio samples is optional. 
For specific exploratory immunogenicity endpoints please refer to Section 
8.2-Immunogenicity Assessments - Exploratory Immunogenicity 
Assessments  
11.5.4 Baseline descriptive Statistics  
Demographic data, baseline characteristics , physical examination, concomitant medications, 
medical history data and study medication exposure will be summarized by treatment group.  
11.5.5 Sub-group Analysis 
The primary endpoint will be summarized and analyzed  by the following subgroups using the 
ITT set:  
The primary endpoint will be summarized and analyzed by the following subgroups using the 
ITT set:  
• Age 
o Up to and including age 65 years 
o Age 66 years and older 
• Sex  
• Race  
11.5.6 Tabulation of Individual Subject Data 
By subject s listing will be produced for each variable by treatment group and study visit. 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 69 of 106 
 
 12. ETHICAL  CONSIDERATION  
12.1 Ethical Conduct of the Study  
The study will be conducted in accordance with the protocol, legal and regulatory requirements, 
and the general principles set forth in the International Ethical Guidelines for Biomedical Research 
Involving Human Subject s (Council for International Organiz ations of Medical Sciences [CIOMS] 
2002), ICH Guideline for Good Clinical Practice, and the Declaration of Helsinki.  
12.2 Institutional Review Board   
It is the responsibility of the Investigator to have prospective approval of the study protocol, 
protocol amendments, informed consent documents, and other relevant documents, e.g., 
recruitment advertisements, if applicable, from the IRB/ IEC. All correspondence with the IRB/EC 
should be retained in the Investigator file. 
The only circumstance in which an amendment may be initiated prior to IRB/ IEC approval is 
where the change is necessary to eliminate apparent immediate hazards to the subject s. In that 
event, the Investigator must notify the IRB/ IEC and Sponsor in writing immediately after the 
implementation.  
They should also be informed of any event likely to affect the safety of the subject s or the continued 
conduct of the clinical study, in particular any change in safety. All updates to the IB will be sent 
to the IRB/IEC and to Health Authorities (Competent  Regulatory Authority), as required by local 
regulation. A progress report is sent to the IRB/IEC at least annually and a summary of the study’s 
outcome at the end of the clinical study.  
12.3  Inform Consent Process  
Informed consent is a process that is initiat ed prior to the individual’s agreeing to participate in the 
study and continues throughout the individual’s study participation. Consent forms will be 
Institutional Review Board (IRB) -approved and the subject  will be asked to read and review the 
document. The Investigator will explain the research study to the subject and answer any questions 
that may arise. A verbal explanation will be provided in terms suited to the subject ’s 
comprehension of the purposes, procedures, and potential risks of the study and of their rights as 
research subject s. Subject s will have the opportunity to carefully review the written consent form 
and ask questions prior to signing.  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 70 of 106 
 
 The subject s should have the opportunity to discuss the study with their family or surrogates or 
think about it prior to agreeing to participate. The subject will sign the informed consent document 
prior to any procedures being done specifically for the study. Subject s must be informed that 
participation is voluntary and that they may withdraw from the study at any time, without 
prejudice. A copy of the informed consent document will be given to the subject s for their records. 
The informed consent process will be conducted and documented in the source document 
(including the date), and the form signed, bef ore the subject undergoes any study -specific 
procedures. The rights and welfare of the subject s will be protected by emphasizing to them that 
the quality of their medical care will not be adversely affected if they decline to participate in this 
study. 
If the trial is involving vulnerable population, video recording of entire informed consent process 
should be ensured depending on the norms of respective country’s regulatory authorities.  
12.4 Insurance Compensation  
The Sponsor certifies that it has taken out a liability insurance policy covering all clinical trials  
under its sponsorship. This insurance policy is in accordance with local laws and requirements. 
The insurance of the Sponsor does not relieve the Investig ator and the collaborators from any 
obligation to maintain their own liability insurance policy. An insurance certificate will be 
provided to the IRB/IEC or regulatory authorities in countries requiring this document. 
12.5 Stipends/Rewards/Compensation  for Participation  
Subjects may be provided with a stipend according to local practice to compensate for the time 
and travel required for study visits and procedures.  
12.6 Subject Confidentiality  
Subject confidentiality and privacy will be  strictly held in trust by the participating Investigators, 
their staff, and the Sponsor and their interventions. This confidentiality is extended to cover testing 
of biological samples in addition to the clinical information relating to subject s. Therefore, the 
study protocol, documentation, data, and all other information generated will be held in strict 
confidence. No information concerning the study or the data will be released to any unauthorized 
third party without prior written approval of the Sponso r. All research activities will be conducted 
in as private a setting as possible.  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 71 of 106 
 
 The study monitor, other authorized representatives of the Sponsor, representatives of the 
Institutional Review Board (IRB), regulatory agencies or pharmaceutical company sup plying 
study product may inspect all documents and records required to be maintained by the investigator, 
including but not limited to, medical records (office, clinic, or hospital) and pharmacy records for 
the Subjects in this study. The clinical study si te will permit access to such records.  
The study subject ’s contact information will be securely stored at each clinical site for internal use 
during the study. At the end of the study, all records will continue to be kept in a secure location 
for as long a  period as dictated by the reviewing IRB, Institutional policies, or Sponsor 
requirements.  
Study subject research data, which is for purposes of statistical analysis and scientific reporting, 
will be transmitted to and stored at sponsors designate d vendor. This will not include the subject ’s 
contact or identifying information. Rather, individual Subject s and their research data will be 
identified by a unique study identification number. The study data entry and study management 
systems used by clinical site s and by designated vendor research staff will be secured and password 
protected. At the end of the study, all study databases will be de- identified and archived  
12.7 Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP  
In the event of any prohibition or restriction imposed (i.e., clinical hold) by an applicable 
regulatory authority in any area of the world, or if the Investigator is aware of any new information 
that might influence the evaluation of the benefits and risk s of the investigational product, Sponsor 
should be informed immediately.  
In addition, the Investigator will inform Sponsor immediately of any urgent safety measures taken 
by the Investigator to protect the study subject s against any immediate hazard, and of any serious 
breaches of this protocol or of ICH GCP that the Investigator becomes aware of.  
13. Data Handling and Record Keeping  
13.1 Source Documents  
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary for validation of the clinical data. Examples of these original 
documents and  data records include, but are not limited to, hospita l records, clinical and office 
charts, laboratory notes, memoranda, subject s’ memory aid or evaluation checklists, pharmacy 
dispensing records, recorded data from automated instruments, copies or transcriptions certified 
after verification as being accurat e and complete, microfiches, photographic negatives, microfilm 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 72 of 106 
 
 or magnetic media, x -rays, and subject files and records kept at the pharmacy, at the laboratories, 
and medico -technical departments involved in the clinical trial. All information on the  CRF w ill 
be traceable to these source documents, which are generally maintained in the subject ’s study file.  
The source documents will include a copy of the signed Informed Consent/ Health Insurance 
Portability and Accountability Act (HIPAA) authorization. The source document data collection 
forms for screening. Outpatient visits and AEs will also serve as CRF data collection instruments.  
The Investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness 
of the data reported. Sou rce documents are maintained for recording data for each subject  enrolled 
in this clinical trial. Study subject s’ data collected on the CRF during the trial will only be 
identified by subject number. If, as an exception, it is necessary for safety or regulatory reasons to 
identify the subject , both the Sponsor and the Investigator are bound to keep this information 
confidential.  
13.2 Case Report Forms (CRF)  
As used in this protocol, the term CRF should be understood to refer to either a paper form or an 
electronic data record or both, depending on the data collection method used in this trial.  
A CRF is required and should be completed for each included subje ct. The completed original 
CRFs are the sole property of Vaxart  and should not be made available in any form to third parties, 
except for authorized representatives of Vaxart or appropriate regulatory authorities, without 
written permission from Vaxart .  
The Investigator has ultimate responsibility for the collection and reporting of all clinical, safety, 
and laboratory data entered on the CRFs and any other data collection forms (source documents) 
and ensuring that they are accurate, authentic/original, at tributable, complete, consistent, legible, 
timely (contemporaneous), enduring, and available when required. 
The CRFs must be signed by the Investigator or by an authorized staff member to attest that the 
data contained on the CRFs are true. Any corrections  to entries made in the CRFs or source 
documents must be dated, initialed, and explained (if necessary) and should not obscure the 
original entry.  
13.3 Data Collection and Management Responsibility  
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the 
site Investigator . The Investigator is responsible for ensuring the accuracy, completeness, 
legibility, and timeliness of the data reported.  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 73 of 106 
 
 All sour ce documents should be completed in a neat, legible manner to ensure accurate 
interpretation of data.  Hardcopies of the study visit worksheets will be provided for use as source 
document worksheets for recording data for each subject enrolled in the study.   
Data recorded in the eCRF) / (CRF) derived from source documents should be consistent with the 
data recorded on the source documents. 
Clinical data (including adverse events (AEs, concomitant medications, and expected adverse 
reactions data) and clinical l aboratory data will be entered into an data capture system that is 21 
CFR Part 11 -compliant. The data system includes password protection and internal quality checks, 
such as automatic range checks, to identify data that appear inconsistent, incomplete, or  inaccurate. 
Clinical data will be entered directly from the source documents . 
13.4 Record Retention  
Study documents should be retained for a minimum of 10 years after the last approval of a 
marketing application in an International Conference on Harminosation (ICH region and until 
there are no pending or contemplated marketing applications in an ICH region or until at least 10 
years have elapsed since the f ormal discontinuation of clinical development of the study drug.  
These documents should be retained for a longer period, however, if required by local regulations. 
No records will be destroyed without the written consent of the Sponsor, if applicable. It is the 
responsibility of the Sponsor to inform the Investigator when these documents no longer need to 
be retained.  
13.5 Property Rights and Data Protection  
Subject s will be assigned a unique identifier by the Sponsor. Any subject records or datasets that 
are transferred to the Sponsor will contain the identifier only; subject names or any information 
which would make the subject identifiable will not be transferred.  
The subject must be informed that their personal study -related data will be used by the Sponsor in 
accordance with local data protection law. The level of disclosure must also be explained to the 
subject who will be required to give consent for their data  to be used as described in the informed 
consent  
The subject  must be informed that their medical records may be examined by clinical quality 
assurance auditors or other authorized personnel appointed by the Sponsor, by appropriate 
IRB/IEC members, and by inspectors from regulatory authorities.  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 74 of 106 
 
 All information, data and documents including results and investigational products provided by 
the Sponsor or its designee are and remain the sole property of the Sponsor. 
The Sponsor may use or exploit all the resul ts at its own discretion.  
14. QUALITY CONTROL AND QUALITY ASSURANCE  
14.1 Early Safety Data Review AND/OR Committee  
Subject safety will be continuously monitored by the Sponsor  or designee, which includes safety 
signal detection during the study. 
An initial safety review for this study is planned for the first 10 sentinel  subjects who will receive 
the high dose  and provide safety data after administration of 2×1011 dose level  in a staggered 
manner, no more than two (2) subjects dosed in a 24 -hour period. All subjects dosed will be 
observed for a minimum of 2 hours post dose.  All safety data collected will be summarized and 
reviewed by the (Sponsor’s internal/external safety monitoring  committee) for agreement of next 
steps.  
14.2 Clinical Trial Site  Monitoring  
Clinical site monitoring is conducted to ensure that the rights and well -being of trial subject s are 
protected, that the reported trial data are accurate, complete, and verifiable, and that the conduct 
of the trial is in compliance with  the currently approved protocol/amendment(s), with International 
Conference on Harmonisation Good Clinical Practice (ICH GCP, and with applicable regulatory 
requirement(s).  
• Monitoring for this study will be performed by the Sponsor or designee  
• Details of clinical site monitoring are documented in a Clinical Monitoring Plan 
(CMP). The CMP describes in detail who will conduct the monitoring, at what 
frequency monitoring will be  done, at what level of detail monitoring will be 
performed, and the distribution of monitoring reports. 
• If needed, i ndependent audits will be conducted to ensure monitoring practices 
are performed consistently across all participating sites and that monitors are 
following the CMP . 
 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 75 of 106 
 
 14.3 Audit and Inspection  
The trial site also may be subject to quality assurance audits by the Sponsor or designees. 
For the purpose of  ensuring compliance with the clinical study protocol, GCP and applicable 
regulatory requirements, the Investigator should permit auditing by or on behalf of the Sponsor 
and inspection by regulatory authorities. 
The investigational site will provide direct  access to all trial related sites, source data/documents, 
and reports for the purpose of monitoring and auditing by the Sponsor, and inspection by local and 
regulatory authorities.  
The Investigator will make every effort to help with the performance of th e audits and inspections, 
giving access to all necessary facilities, data, and documents.  
As soon as the Investigator is notified of a planned inspection by the authorities, he/she will inform 
the Sponsor and authorize the Sponsor to participate in this inspection. 
The confidentiality of the data verified, and the protection of the subject s should be respected 
during these inspections. 
Any result and information arising from the inspections by the regulatory authorities will be 
immediately communicated by t he Investigator to the Sponsor.  
The Investigator shall take appropriate measures required by the Sponsor to take corrective actions 
for all problems found during the audit or inspections. 
14.4 Responsibility of Investigator 
The Investigator is required to ensure compliance with all procedures required by the clinical trial 
protocol and with all trial procedures provided by the Sponsor (including security rules).  
The Investigator agrees to provide reliable data and all inform ation requested by the clinical trial 
protocol (with the help of the CRF, discrepancy resolution form, or other appropriate instrument) 
in an accurate and legible manner according to the instructions provided and to ensure direct access 
to source documents to the Sponsor representatives.  
If any circuit includes transfer of data, particular attention should be paid to the confidentiality of 
the subject ’s data to be transferred. The Investigator may appoint such other individuals as he/she 
may deem appropriate as Sub -investigators to assist in the conduct of the clinical study in 
accordance with the clinical trial protocol.  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 76 of 106 
 
 All Sub -investigators shall b e appointed and listed in a timely manner. The Sub -investigators will 
be supervised by and work under the responsibility of the Investigator. The Investigator will 
provide them with a copy of the clinical trial protocol and all necessary information.  
To pr oviding written summaries of the status of the study to the IRB/IEC annually or more 
frequently in accordance with the requirements, policies, and procedures established by the 
IRB/IEC.  
To notifying the IRB/IEC of SAEs or other significant safety findings as required by IRB/IEC 
procedures. 
Signed copy of Investigator’s undertaking should be provided as an appendix. 
14.5 Responsibility of Sponsor  
The Sponsor of this clinical trial is responsible to regulatory authorities for taking all reasonable 
steps to ensure the proper conduct of the clinical study as regards ethics, clinical study protocol 
compliance, and integrity and validity of the data recorded on the CRFs. Thus, the main duty of 
the monitoring team is to help the Investigator and the Sponsor maintain a h igh level of ethical, 
scientific, technical,  and regulatory quality in all aspects of the clinical study.  
At regular intervals during the clinical study, the site will be contacted, through monitoring visits, 
letters,  or tele-health appointment , by a repre sentative of the monitoring team to review study 
progress, Investigator and subject compliance with clinical study protocol requirements, and any 
emergent problems.  
These monitoring visits will include but not be limited to review of the following aspects:  subject ’s 
informed consent, subject  recruitment and follow -up, SAE documentation and reporting, AE 
documentation, IP allocation, IP accountability, concomitant therapy use, and quality of data. 
14.6 Protocol Deviation 
A protocol deviation is any noncompliance with the clinical trial protocol, ICH GCP, or Manual 
of Procedures (MOP) requirements. The noncompliance may be either on the part of the subject , 
the Investigator , or the study site staff. As a result of deviation s, corrective actions are to be 
developed by the site and implemented promptly.  Details can be found in the study specific 
Protocol Deviation Plan or the Clinical Monitoring Plan. 
 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 77 of 106 
 
 15. PUBLICATION AND DATA SHARING POLICY  
The Sponsor will comply with the requirements for publication of study results. In accordance  
with standard editorial and ethical practice, the Sponsor will generally support publication of  
multicenter studies only in their entirety and not as individual site data. In this case, a  coordinating 
investigator will be designated by mutual agreement. Requests for publication of  site-specific data 
should be presented to the Sponsor for review and approval at least 90  days prior to submission 
for publication.  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 78 of 106 
 
 16. REFERENCES  
Atmar, R.L., Estes, M.K., 2012. Norovirus Vaccine Development –Next Steps. Expert Rev 
Vaccines 11, 1023–1025. 
Bresee, J.S., Widdowson, M., Monroe, S.S., Glass, R.I., 2002. Foodborne Viral Gastroente ritis: 
Challenges and Opportunities. CLIN INFECT DIS 35, 748–753.  
Esposito, S., Principi, N., 2020. Norovirus Vaccine: Priorities for Future Research and 
Development. Front Immunol 11, 1383.  
Glass, R.I., Parashar, U.D., Estes, M.K., 2009. Norovirus Gastroenteritis. N Engl J Med 361, 
10.1056/NEJMra0804575.  
Kim, L., Liebowitz, D., Lin, K., Kasparek, K., Pasetti, M.F., Garg, S.J., Gottlieb, K., Trager, G., 
Tucker, S.N., 2018. Safety and immunoge nicity of an oral tablet norovirus vaccine, a phase I 
randomized, placebo-controlled trial. JCI Insight 3, e121077.  
Liao, Y., Hong, X., Wu, A., Jiang, Y., Liang, Y., Gao, J., Xue, L., Kou, X., 2021. Global 
prevalence of norovirus in cases of acute gastroe nteritis from 1997 to 2021: An updated 
systematic review and meta -analysis. Microbial Pathogenesis 161, 105259.  
Liebowitz, D., Gottlieb, K., Kolhatkar, N.S., Garg, S.J., Asher, J.M., Nazareno, J., Kim, K., 
McIlwain, D.R., Tucker, S.N., 2020. Efficacy, immunogenicity, and safety of an oral influenza 
vaccine: a placebo -controlled and active -controlled phase 2 human challenge study. The Lancet 
Infectious Diseases 20, 435–444.  
Vega, E., Barclay, L., Gregoricus, N., Shirley, S.H., Lee, D., Vinjé, J., 2014. Genotypic and 
Epidemiologic Trends of Norovirus Outbreaks in the United States, 2009 to 2013. J Clin 
Microbiol 52, 147–155.  
  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 79 of 106 
 
 Appendix 1: Clinical Laboratory Tests  
• The tests detailed in  Table  10 will be performed by the local laboratory, unless 
otherwise specified.  
• Protocol- specific requirements for inclusion or exclusion of subject are detailed in 
Section  5. 
• Additional tests may be performed at any time during the study as determined 
necessary by the Investigator or required by local regulations.  
• Investigators must document their review of each laboratory safety report.  
Table 10 Protocol- Required Laboratory Assessments  
Urine drug screen  amphetamines, methamphetamines, methadone, barbiturates, benzodiazepines, 
cocaine, opiates, methylenedioxymethamphetamine, phencyclidine, 
tetrahydrocannabinol  
Other laboratory 
assessments Hepatitis B surface antigen, hepatitis C virus antibody, and human immunodeficiency 
virus antibody types 1 and 2 (Screening only)  
Female subject s serum pregnancy tests  at screening  
Female subjects Point -of-Care  urine pregnancy tests prior to dosing at Day 1 
 
Appendix 2: Country -specific Requirements  
Not applicable. 
Appendix 3: Adverse Event s Grading 
Grading of Solicited Adverse Events  
Subjects should be instructed to rate S olicited Symptoms of Reactogenicity that are collected 
within their Solicited Symptom Diary based on the severity scale presented in  Table 11. 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 80 of 106 
 
 Table 11 Grading of Solicited Symptoms of Reactogenicity  
 
Symptom  Grading 
Normal Mild Moderate  Severe Life Threatening  
0 Grade 1 Grade 2 Grade 3 Grade 4 
Fever  
(oral temp)  < 
100.4°F  
(< 38.0°C)100.4 – 101.1°F  
(38.0 – 38.4°C)  101.2 – 102.0°F  
(38.5 – 38.9°C)  102.1 – 104°F  
(39.0 – 40°C)  > 104.0°F  
(>40°C)  
Headache  None  No interference with 
activity  Repeated use of 
nonnarcotic pain 
reliever > 24 hours or 
some interference 
with activity  Significant; any use of 
narcotic pain reliever 
or prevents daily 
activity  ER visit or 
hospitalization  
Myalgia  
(muscle 
pain)  None  AE easily tolerated, 
causing minimal 
discomfort and does 
not interfere with 
everyday activitiesa Adverse event 
sufficiently 
discomforting to 
interfere with 
everyday activities  Adverse event 
prevents normal 
everyday activities or 
requires medical 
advice  ER visit or 
hospitalization  
Abdominal 
Pain None  No interference  with 
activity  Some  interference  
with activity  not 
requiring  medical  
intervention  Prevents  daily  activity  
and requires medical  
intervention  ER visit or 
hospitalization  
Anorexia  None  No interference  with 
activity  Some  interference  
with activity  not 
requiring  medical  
intervention  Prevents  daily  activity  
and requires medical  
intervention  ER visit or 
hospitalization  
Nausea  None  No interference with 
activity or 1 to 2 
episodes Some interference 
with activity or >2 
episodes Prevents daily 
activity, requires 
outpatient IV 
hydration  ER visit or 
hospitalization for 
hypotensive shock  
Vomiting  None  No interference with 
activity or 24 hours  Some interference 
with activity or 24 
hours  Prevents daily 
activity, requires 
outpatient IV 
hydration  ER visit or 
hospitalization for 
hypotensive shock  
Diarrhea  None  2 to 3 loose stools or 
< 400 gms/24 hours  4–5 stools or 400 
to 800 gms/24  hours 6 or more watery 
stools or > 800gms/24 
hours or requires 
outpatient IV 
hydration  ER visit or 
hospitalization  
Malaise/ 
Fatigue  None  No interference  with 
activity  Some  interference  
with activity  Significant;  prevents 
daily  activity  ER visit or 
hospitalization  
a Everyday activity include attendance at work, school, and usual habits of the subject s. 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 81 of 106 
 
 Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information  
Definitions  
Postmenopausal female: 
• A postmenopausal state is defined as no menses for 12 months without an alternative medical 
cause.  
−  A negative pregnancy test will be required for all female subjects prior to study 
drug administration, as out lined in the S oA (Table  1). 
Contraception Guidance  
Male Subjects: 
Male subject s are eligible to participate if they agree to the following from informed consent 
through 60 days after the last dose of study drug : 
• Refrain from donating sperm . 
       PLUS: 
• Be abstinent from intercourse as their preferred and usual lifestyle (abstinent on a long term 
and persistent basis) and agree to remain abstinent . 
            OR 
• Must agree to use contraception/barrier (a male condom) . 
Collection of Pregnancy Information 
Female subject s or Male subjects with partners who become pregnant: 
• The investigator will attempt to collect pregnancy information on any female subject s or 
male subject ’s female partner who becomes pregnant while the male subject  is in this study.  
After obtaining the necessary signed ICF from the pregnant female subject or male subject ’s 
female partner directly, the investigator will record pregnancy information on the appropriate form 
and submit it to the Sponsor within 24 hours of learning of the pregnancy. The Sponsor will attempt 
to follow the female subject  or female partner to determine the outcome of the pregnancy. 
Information on the status of the mother and child will be forwarded to the Sponsor. The Sponsor 
will follow the female subject or female partner until birth or termination of pregnancy when 
possible. Any termination  of the pregnancy will be reported regardless of fetal status (presence or 
absence of anomalies) or indication for the procedure.   
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 82 of 106 
 
 Appendix 5: Adverse Events of Special Interest  
An Adverse event of special interest (AESI) is a serious or non -serious adverse events of scientific 
and medical concern for which ongoing monitoring and rapid communication by the Investigator  
to the Sponsor is indicated. The following adverse events  (AEs) for potential immune -mediated 
medical conditions as well as events associated with thrombosis and thrombocytopenia are AEs of 
special interest (AESIs) and include new onset of chronic illness (NOCIs). These events should be 
monitored f or actively and reported to the Sponsor in an expedited manner as outlined in Section  
9. 
Table 12:  Adverse Events of Special Interest  
Gastrointestinal disorders:  Liver disorders:  
• Celiac disease  • Autoimmune cholangitis  
• Crohn’s disease  • Autoimmune Hepatitis  
• Ulcerative colitis  • Primary biliary cirrhosis  
• Ulcerative proctitis  • Primary sclerosing cholangitis  
Metabolic diseases:  
• Addison’s disease  • Diabetes mellitus type 1  
• Autoimmune thyroiditis (including 
Hashimoto thyroiditis)  • Grave’s or Basedow’s disease  
Coagulopathy:  
• Acquired amegakaryocytic 
thrombocytopenia  • Amegakaryocytic thrombocytopenia  
• Axillary vein thrombosis  • Cavernous sinus thrombosis  
• Cerebral venous thrombosis  • Deep vein thrombosis  
• Disseminated intravascular coagulation  • Embolism venous  
• Hepatic vein thrombosis  • Immune thrombocytopenia  
• Intracranial venous sinus thrombosis  • Mesenteric vein thrombosis  
• Portal vein thrombosis  • Pulmonary embolism  
• Pulmonary thrombosis  • Pulmonary venous thrombosis  
• Severe fever with thrombocytopenia 
syndrome  • Subclavian vein thrombosis  
• Thrombocytopenia  • Thrombocytopenia purpura  
• Thrombotic thrombocytopenia purpura  • Thrombosis  
• Transverse sinus thrombosis  • Vena cava embolism  
• Vena cava thrombosis  • Venous thrombosis  
Musculoskeletal disorders:  
• Antisynthetase syndrome  • Polymyalgia rheumatic  
• Dermatomyosotis  • Polymyositis  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 83 of 106 
 
 • Juvenile chronic arthritis (including Still’s 
disease)  • Psoriatic arthropathy  
• Mixed connective tissue disorder  • Relapsing polychondritis  
• Scleroderma, including diffuse systemic 
form and CREST Syndrome  • Rheumatoid arthritis  
• Systemic lupus erythematous   • Systemic sclerosis   
• Spondyloarthritis, including ankylosing spondylitis, reactive arthritis (Reiter’s Syndrome) and 
undifferentiated spondyloarthritis.  
Neuroinflammatory disorders:  
• Acute disseminated encephalomyelitis, including site specific variants (e.g., non -infections encephalitis, 
encephalomyelitis, myelitis, myeloradiculomyelitis)  
• Immune related peripheral neuropathies and plexopathies, including chronic inflammatory demyeli nating 
polyneuropathy, multifocal motor neuropathy and polyneuropathies associated with monoclonal 
gammopathy  
• Cranial nerve disorders, including 
paralysis/paresis (e.g., Bell’s palsy)  • Guillain -Barre syndrome, including Miller Fisher 
syndrome and other var iants  
• Multiple sclerosis  • Narcolepsy  
• Optic neuritis  • Transverse Myelitis  
• Myasthenia gravis, including Eaton -Lambert syndrome  
Skin disorders:  
• Autoimmune bullous skin diseases 
(including pemphigus, pemphigoid  and 
dermatitis herpetiformis  • Rosacea  
• Alopecia aerate  • Cutaneous lupus erythematosus  
• Erythema nodosum  • Psoriasis  
• Morphoea  • Sweet’s syndrome  
• Lichen planus  • Vitiligo  
Vasculitis:  
• Large vessels vasculitis including:  giant cell arteritis such as Takayasu’s arteritis and temporal arteritis  
• Medium sized/and or small vessels vasculitis including:  polyarthritis nodosa, Kawasaki’s disease, 
microscopic polyangiitis, Wegener’s granulomatosis, Churg -Strauss syndrome (allergic granulomatous 
angititis), Buerger’s disease thromboangitis obliterans), nerotizing vasculitis and anti -neutrophil 
cytoplasmic an tibody (ANCA) positive vasculitis (type unspecified), Henoch -Schonlein purpura, Behcet’s 
syndrome, leulocytoclassic vasculitis  
Others: 
• Autoimmune glomerulonephritis (including IgA nephropathy, glomerulonephritis rapidly progressive, 
membranous glomerulonephritis, membranaoprolifative glomerulonephritis, and mesangioproliferative 
glomerulonephritis)  
• Antiphospholipid syndrome  • Pernicious an emia  
• Autoimmune hemolytic anemia  • Raynaud’ phenomenon  
• Autoimmune myocarditis/cardiomyopathy  • Sarcoidosis  
• Autoimmune thrombocytopenia  • Sjogren’s syndrome  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL  Page 84 of 106 • Goodpasture syndrome • Stevens -Johnson Syndrome
• Idiopathic pulmonary fibrosis • Uveitis
Appendix 6.0 Protocol Version History  
Name of the Document with 
Version Number  Date Summary of Changes and 
Rationale 
VERSION 1.0  12 OCT 2022  INITIAL VERSION  
VERSION 2.0 ` 09 FEB 2023  AMENDMENT 1.0 
VXA-NVV-202 Protocol Amendment 1 (V ersion. 2.0), 09 Feb 2023 
Overall Rationale for the Amendment:  
The original version of this phase 2 Norovirus protocol (VXA- NVV -2022) was finalized in October 
2022 and submitted for CBER (US FDA) , MedSafe  (New Zealand Regulatory Authority) and IRB 
review.  Although approvals were obtained, the study design was modified to a US only study to include 
10 open label sentinel subjects receiving the high dose. After SMC review of the sentinel safety data 1 
week after dosing, a 125 subject double blind randomization portion of the study will follow. 
The table below summarizes the changes incorporated into Amendment 1 as well as a brief rationale for 
each modification.  
Section No. 
& Title Description of Change  Brief Rationale  
All headers  Updated to date of amendment  All headers have been updated to 
match the date of the Amendment 1  
Cover page  Update information for protocol version and date and 
prior version  To provide accurate information 
Protocol Title  
Page  Amendment No: 2 and Date of Amendment -09 Feb 
2023  To provide accurate information  
Entire protocol Removed any referenced to  subjects Legally 
Authorized Representative   This study is enrolling health 
volunteers  
Protocol 
Synopsis Contract Research Organization:    
 
. 
Updated to:  
 
 
 To provide accurate information  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 85 of 106 
 
 Protocol 
Synopsis trial 
Arms  Changed sample for the randomized double -blind  
portion of the study:  Trial Arms:  
Arm 1: Bivalent GII.4/GI.1 medium dose vaccine 
(VXA -GII.4- NS plus VXA -G1.1 -NN) 5×1010 tablets; 
total dose is 1×1011 IU/dose (n =50) 
Arm 2: Bivalent GII.4/GI.1 high dose vaccine (VXA -
GII.4 -NS plus VXA -G1.1 -NN) 1×1011 table ts; total 
dose is 2×1011 IU/dose (n50) and (sentinel n=10)  
Arm 3: Placebo tablets (n =25) To provide accurate information and 
reflect changes to the design of the 
study  
Protocol 
Synopsis Subject 
Population  Removed 613 sample size and replaced with 125 
sample size  Changed study design and sample  
size of the study  
Endpoints:  
Immunogenicity  Added Day 8 to Serum anti IgA for both GI.1 and 
GII.4, Serum BT50  Updated bio sample assays at Day 8  
Endpoints:  
Immunogenicity  Removed : PBMC: Anti - IgA Antibody Secreting Cells 
(ASC) for both GI.1 and GII.4 by ELISpot at Day 8  PBMC samples will not be collected 
in this study  
Protocol 
Synopsis  : 
Description of 
Sites/Facilities  Removed the country of New Zealand. This study will 
be a single country study.  Single country study -USA only.  
Protocol 
Synopsis -trial 
design  Changed sample size from 613 to 125 and added the 
following text for the sentinel subjects:  The sentinel 
subjects will be enrolled in a staggered design, in which 
no more than two (2) subjects are dosed per 24 -hours. 
All sentinel subjects will be observed for safety at least 
2 hours post dose. After the ten (10) sentinel subjects 
have been enrolled, and if no dose -related toxicities are 
observed, and upon the recommendation of the Safet y 
Monitoring Committee (SMC) following review of 
safety data up to one week post dose, enrollment of the 
randomized double -blind study will be initiated.  a. Sample  size modification to 
accurately reflect current study.   
b. The original version of the 
protocol allowed for enrollment 
of the 10 sentinel subjects 
without limitations. This 
amendment limits sentinel 
dosing to 2 subjects per 24 -hour 
period and extends the sentinel 
observation period to 2 hours 
post dose. These parameters 
were added in response to 
MedSaf e (New Zealand 
Regulatory Authority) request, 
and not due to any new safety 
findings or concerns. Although 
the study will no longer include 
sites in New Zealand after 
modification of the study design 
and size, Vaxart has decided to 
keep the increased senti nel safety 
oversight .  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 86 of 106 
 
 Protocol 
Synopsis -Figure 
1-Study Design  Arm 2 is the High Dose arm. Both the High and 
Medium dose arms are labelled as Arm 1 in the study 
design schematic in error.  
 a. Schematic  updated and replaced.  
 
Protocol 
Synopsis -
Planned Number 
of Subjects  Updated sample size to 125: A total of 125  healthy 
adult male and female subjects aged ≥18 years and ≤80 
years will be , randomized and assigned to 
investigational vaccine during this study.  To accurately reflect the stu dy design 
sample size  
Protocol 
Synopsis -
Exclusion 
Criteria Exclusion #5: Removed History of Gilberts Syndrome.  
Left blank intentionally  to ensure exclusion criteria 
numbers reconcile with the EDC.  
 
 
 
 
 
 
 
Exclusion #14, d : Presence of any of the following 
conditions known to increase risk of thrombosis within 
6 months prior to screening:  letter “v”: Recent 
clinically significant infection.  Gilbert’s syndrome is a common 
inherited condition where the liver 
doesn’t properly process bilirubin, 
leading to harmless elevated bilirubin 
lab results. Gilbert’s has not been an 
exclusion in any previous protocols 
for our vaccines and was added in 
error in the earlier version of NVV 
202 before the decision was made 
not to require chemistry labs during 
this trial. The intent was to avoid 
potential confounding of safety labs 
in subjects with known Gilbert’s. 
There have been no safety signals or 
concerns with Vaxart’s oral vaccine 
platfor m with regard to liver 
enzymes or bilirubin.  
 
Severe covid infection is known to 
be associated with risk of 
thrombosis . Since we are not 
screening specifically for covid 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 87 of 106 
 
 added the following : v. Including hospitalization for 
COVID -19 infection  
 
 
 
 infection, this is a way to exclude 
severe covid infections.  
 
Protocol 
Synopsis -Other 
Exclusions  Exclusion #28: History of hypersensitivity or allergic 
reaction to any component of the investigational 
vaccine, including but not limited to fish gelatin 
allergy.   Added the word “gelatin” as this was 
omitted in error in last pro tocol 
version.  
Protocol 
Synopsis - Study 
Duration  Open Label Period (for sentinel subjects) : 
8 days (dosing and collection of Solicited 
Symptoms and continue through Active and 
Follow Up Period)  
Added “staggered to the previous text:  
8 days (staggered dosing and collection of 
Solicited Symptoms and continue through Active 
and Follow Up Period)  Accurate reflection of the dosing 
schedule for the sentinels  
Protocol  
Synopsis  : 
Sample Size 
Justification  Sample Size Justification:  
A sample size of 613 randomized subjects (245 each in 
medium and high dose levels and 123 in placebo) are  
required to achieve 80% power, at the 7% significance 
level (one -sided) using a 2 -group fisher exact test with  
equal allocation to each dose level. Calculation 
assumes a difference of 10.2% in MSD IgA fold rise 
between  the two dose groups (72.7 % Vs. 62.5%). 
Placebo was added for safety comparison.  
Updated to:  
A sample size of 125 randomized subjects (50 each in 
medium a nd high dose levels and 25 in placebo) in 
addition to 10 sentinel subjects are not based on formal 
statistical testing but rather based on clinical judgement 
and predicted to yield meaningful safety and 
immunogenicity results . Placebo was added for safety 
comparison.  Accurately reflect sample size 
change and impact on statistics  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 88 of 106 
 
  
 
 
 
Protocol 
Synopsis  : Table 
1 : Schedule of 
Activities  Updated SOA to align with modifications  to protocol 
dated 13 Oct 2022.  
1. Updated immunogenicity  testing.  
2. Remove PBMC visits.  
3. Added a Day  8 serum and whole blood sample 
collection.  
4. Added a Day 180 serum, nasal and saliva sample 
collection.  
5. Made Day 180 an in person visit at the clinic.  
6. Added a SOA grid for Sample Collection for 
immunogenicity  Assessments -all subjects.   
7. Added clarification of procedures for Early 
Termination subjects  
8. Updated legend  and superscripts in the SOA grid  
9. Added temperature to Vital Signs -legend “c”  Now 
reads: temperature, blood pressure, heart rate, and 
respiratory rate will be measured  after the subject 
has been resting for 5 minutes  Provide accurate information specific 
to the SOA   
Protocol 
Synopsis  : Trial 
Rationale  Last paragraph:  
Original text:  
The current Phase 2 dose confirmation study is 
designed to assess the safety and immunogenicity of 
GI.1/GII.4 bivalent vaccine with a 1 -dose vaccination 
schedule in healthy volunteers (≥18 years and ≤80 
years).  
Updated text : 
The current Phase 2 dose confi rmation study is 
designed to assess the safety and immunogenicity of 
GI.1/GII.4 bivalent vaccine with a single vaccine dose 
in healthy volunteers (≥18 years and ≤80 years).  Provide accurate information specific 
to the study design  
   
2.2.3  Clinical 
experience with Updated non clinical experience  Provide accurate information specific 
to the study design  and updates  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 89 of 106 
 
 Bivalent GI.1 
and GII.4 
vaccine  Removed VXA -NVV -106 text since it was specific to 
the low titer/high tablet lot and was not included in the 
IB 
2.3 Trial 
Rationale  Original text:  
The current Phase 2 dose confirmation study is 
designed to assess the safety and immunogenicity  of 
GI.1/GII.4 bivalent vaccine with a 2 -dose vaccination 
schedule in healthy volunteers (≥18 years  and ≤80 
years).  
Updated to:  
The current Phase 2 dose confirmation study is 
designed to assess the safety and immunogenicity of 
medium and high dose levels  of GI.1/GII.4 bivalent 
vaccine with a single 2-dose vaccination schedule in 
healthy volunteers (≥18 year s and ≤80 years).  Provide accurate information specific 
to the study design   
3.2.1 Primary 
End Points  Added Day 8 to the following calculation.   
• Geometric mean concentration (GMC) at Day 
8 and Day 29  
• Geometric mean fold rise (GMFR) from Day 1 
to Day 8 to Day 29  Provide accurate information specific 
to the modified study design and bio -
sample analysis for serum samples  
 The current Phase 2 dose confirmation study is 
designed to assess the safety and immunogenicity of 
medium and high dose levels of GI.1/GII.4 bivalent 
vaccine with a single dose2 -dose vaccination schedule 
in healthy volunteers (≥18 years and ≤80 years).   
3.2.2 
Explora tory- End 
Points -
Immun ogenicity  Added Day 8  to the following:  
• Serum:  
• Antibody titers for both GI.1 and GII.4 by 
Histo -blood group antigen (HBGA) -Blocking 
Assay (BT50) - geometric mean titer (GMT) 
and GMFR at Day 8, Day 29 and Day 180  
• Anti- IgG for both GI.1 and GII.4 by MSD 
assay -GMC and GMFR at Day 8, Day 29 and 
Day 180  
• Anti- IgA for both GI.1 and GII.4 by MSD 
assay - GMC and GMFR at Day 8 Day 180  
Removed PBMC sampling and analysis  Provide a ccurate information specific 
to the modified study design and bio -
sample analysis for serum , nasal, 
saliva and whole blood sampling  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 90 of 106 
 
 • Nasal Swab:  
• Anti- IgA for both GI.1 and GII.4 - GMC and 
GMFI at Day 8, Day 29 and Day 180  
• Saliva:  
• Anti- IgA for both GI.1 and GII.4 - GMC and 
GMFI at Day 8, Day 29 and Day 180  
Added Day 1 and Day 8 collection to the following:   
• Fixed Whole Blood (required for blood draw, 
optional for testing)  
• B-cell immunophenotyping - Day 1, Day 8 and 
Day 29  
4.1 Overall 
Description of 
Trial Design  Original text:  
This is a multi -center, double -blind, randomized, 
placebo -controlled, single dose, dose ranging study in 
healthy volunteers (≥18 years and ≤80 years). The 
study will enroll 10 sentinel subjects in an open label 
period and randomize 613 subjects in three arms.  
Updated text:  
This is a multi -center, double -blind, randomized, 
placebo -controlled, single dose, dose ranging study in 
healthy volunteers (≥18 years and ≤80 years). The 
study will enroll 10 sentinel subjects in an open label 
period and randomize 125 subjects in three arms.  
Original Text:  
The first 10 sentinel subjects will receive the open label 
high dose of active vaccine (2×1011) shown in Table 2. 
If no dose -related toxicities are observed, and upon the 
recommendation of the SMC following review of 
safety data, enrollment of the remaining subjects wi ll 
be initiated.  
Updated Text:  
The first 10 sentinel subjects, in a staggered manner of 
up to 2 subjects per 24 -hour period, will receive the 
open label high dose of bi -valent active vaccine 
(2×1011) shown in Table 2. If no dose -related toxicities 
are observed, and upon the recommendati on of the  
 
Accurately reflect sample size 
change  from 613 to 125 for the 
double -blind  randomized portion of 
the study  
 
 
 
 
 
 
 
 
 
 
 
The original version of the protocol 
allowed for enrollment of the 10 
sentinel subjects without limitations. 
This amendment limits sentinel 
dosing to 2 subjects per 24-hour 
period and extends the sentinel 
observation period to 2 hours post 
dose.  
  
 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 91 of 106 
 
 SMC following review of safety data, enrollment of the 
randomized double -blind study will be initiated.  
Table 2 Sentinel Subjects deleted.  
Updated Table 2: Sentinel Subjects   
 
 
Updated Table 2 accurately reflects 
the study design modifications for 
the sentinel subjects  
4.1 4.1  Overall 
Description of 
Trial Design  Table 3: Study Design  
1. Updated the table to reflect the new sample size
and sample size per arm.  
2. Added a row for the sentinels to Table 3  
Abbreviations: IU: International Units,  
Corrected to:  Infectious Units (IU)  Provide accurate information specific 
to the modified study design  
Table 4  : 
 Original text:  
Open Label Period (for 10 sentinel subjects) -8 days ( 
dosing and collection of Solicited Symptoms and 
continue through Active and Follow Up Period)  
Updated to:  Provide accurate information specific 
to the modified study design  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 92 of 106 
 
 Added “staggered”  
Open Label Period (for 10 sentinel subjects)  8 days  
(staggered dosing and collection of Solicited Symptoms 
and continue through Active and Follow Up Period)  
5.1 Inclusion 
Criteria Inclusion #3:  
Original text:  
3. Body mass index (BMI) between 17.0 and 35.0 
kg/m2 at screening SNG.  
Updated text:  
Removed SNG -erroneous text  and clarify range:  
3. Body mass index (BMI) > 17.0 and < 35.0 kg/m2 at
screenin g Correct a text error  
Section 5.1 
Inclusion 
Criteria-
Exclusion 
Criteria Exclusion #14:  
Original Text  
14. Any of the following history or conditions that 
may lead to higher risk of clotting events and/or 
thrombocytopenia:  
e. Family or personal history of bleeding or 
thrombosis.  
f. History of heparin -related thrombotic events, 
and/or receiving  heparin treatments.  
g. History of autoimmune or inflammatory 
disease.  
h. Presence of any of the following conditions known 
to increase risk of thrombosis within 6 months prior to 
screening:  
i. Recent surgery other than removal/biopsy of 
cutaneous lesions  
ii. Immobility (confined to bed or wheelchair for 3 or 
more successive days)  No change to actual t ext for 
Exclusion 14,h. Changed  
classification (i to a, ii to b, etc.)  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 93 of 106 
 
 iii. Head trauma with loss of consciousness or 
documented brain injury  
iv. Receipt of anticoagulants for 
prophylaxis of thrombosis  
v. .Recent clinically significant 
infection  
Updated text:  
14. Any of the following history or conditions that 
may lead to higher risk of clotting events and/or 
thrombocytopenia:  
a) Family or personal history of bleeding or 
thrombosis.  
b) History of heparin -related thrombotic events, 
and/or receiving heparin treatments.  
c) History of autoimmune or inflammatory disease.  
d) Presence of any of the following conditions 
known to increase risk of thrombosis within 6 
months prior to screening:  
i. Recent surgery other than removal/biopsy of 
cutaneous lesions  
ii. Immobility (confined to bed or wheelchair for 
3 or more successive days)  
iii. Head trauma with loss of consciousness or 
documented brain injury  
iv. Receipt of anticoagulants for prophylaxis of 
thrombosis  
v. Recent clinically significant infection  
Section 5.1 
Inclusion 
Criteria-
Exclusion 
Criteria Exclusion #28  
Original text:  
29. History of hypersensitivity or allergic reaction to 
any component of the investigational vaccine, 
including but not limited to fish allergy.  
Updated text:  
Added “gelatin”  Corrected  exclusion criteria  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 94 of 106 
 
 28. History of hypersensitivity or allergic reaction 
to any component of the investigational vaccine, 
including but not limited to fish gelatin allergy.  
6.1Investigation
al Product 
Description  Original Text:  
VXA -G1.1 -NN and VXA -GII.4- NS are E1/E3 -deleted, 
replication -incompetent, adenovirus 5 vaccine vectors 
designed for use as vaccines for prevention of NoV 
infection. The vaccine vectors encode for a full -length 
VP1 gene of either Norwalk virus (VXA -G1.1 -NN 
vaccine) or Sydney virus (VXA -GII.4- NS vaccine). In 
addition to the transgene cassette, a second hCMVie 
promoter is also present in the vaccine construct which 
is used to express an RNA sequence that ac ts as an 
adjuvant. The adjuvant is a short hairpin RNA 
expressed off a promoter such that only target cells in 
the intestine that express antigen will also express the 
adjuvant. This is likely to result in a tight association of 
antigen with adjuvant in vi vo. 
 
Updated text:  
VXA -G1.1 -NN and VXA -GII.4- NS are E1/E3 -deleted, 
replication -incompetent, adenovirus 5 vaccine vectors 
designed for use as vaccines for prevention of  NoV 
infection. The vaccine vectors encode for a full -length 
VP1 gene of either Norwalk virus (VXA -G1.1 -NN 
vaccine) or Sydney virus (VXA -GII.4- NS vaccine). In 
addition to the transgene cassette, a second hCMVie 
promoter is also present in the vaccine constructs which 
is used to express a ribonucleic acid (RNA) sequence 
that acts as an adjuvant. The adjuvant is a short hairpin 
RNA expressed off a promoter such that only target 
cells in the intestine that express antigen will also 
express the adjuvant. This is likely to result in a tight 
association of antigen with adjuvant in vivo.  
 Provide accurate information s pecific 
to the Investigational Product  
6.7.1 
Randomization 
procedures  Original text:  
After signing an informed consent, the subjects will 
undergo screening assessments to determine study 
eligibility over a 45 -day Screening Period. On Day 1, 
subjects will be randomized in a 2:2:1 ratio to one of Provide accurate information specific 
to how screen failed subjects will be 
captured in the EDC  (reason for 
screen failure)  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 95 of 106 
 
 the three treatment arms to receive active va ccine or 
placebo, as follows (Table 6).  
Updated Text:  
After signing an informed consent, the subjects will 
undergo screening assessments to determine study 
eligibility over a 45 -day Screening Period. All subjects 
who sign a study specific informed consent form will 
have data entered into the EDC . On Day 1, subjects 
will be randomized in a 2:2:1 ratio to one of the three 
treatment arms to receive active vaccine or placebo, as 
follows (Table 6).  
 
 
7.1.Procedure to 
be followed on 
screening (Day -
45 to Day -1) Original text -bullet 5:  
•Measure subject’s temperature (oral).  
Updated text:  
•Measure subject’s temperature (oral). Oral temperature 
is preferred for all visits. If unavailable, it is acceptable 
for clinical study sites to measure subject’s temperature 
according to site usual standard using tympanic 
thermometer instead of oral and this should be clearly 
documented. All subjects must use the study -provided 
thermometer for daily oral temperature checks for 
solicited symptoms in the week following vaccine dose . 
Original text -bullet 7  
•Perform a urine pregnancy test for all female s ubjects 
at screening.  
Updated text:  
•Perform a urine pregnancy test for all female subjects 
at screening. At screening all women will have a 
negative serum HCG. Prior to dosing all women will 
have a negative urine HCG.  Allow alternatives to oral 
temperatures  and clarify the 
preferred  use of the sponsor provided 
thermometers for reporting  daily 
diary specific temperatures . 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clarify that all subjects must have a 
negative pregnancy test  (serum) at 
screening and a negative pregnancy 
test ( urine) prior to dosing.  
7.1.2
 Procedur
e to be followed Procedures to be followed during the Active Study 
Period (Day 1 to Day 29): Subjects will return the site Provide accurate information specific 
to the original intent of the study 
procedures  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 96 of 106 
 
 during Active 
Study Period 
(Day 1 to Day 
29) (as specified in SOA) and a blood sample will be 
collected for immunogenicity assessment.  
Update to: Subjects will return to the site (as specified 
in SOA) and blood, nasal and saliva samples will be 
collected for immunogenicity assessment.  
Added : 
For the subjects enrolled into the open label sentinel 
study arm, the site staff must observe the subjects at the 
site, in the ≥18 to ≤80 years old age group, for at least 2 
hours after study drug administration for any acute 
reactions. Any acute reactions are to be recorded in the 
subject’s source documents, on the AE page of the 
eCRF, and on a serious adverse event (SAE) form, as 
applicable.  
Original te xt: 
The Investigator or appropriately qualified designee 
will review the Diary data online following 
vaccination, to evaluate subject compliance and as part 
of the ongoing safety review. Daily review is optimal 
during the active Diary period. Any solicited  symptom 
marked as Grade 3 should be specifically reviewed 
with the subject to ensure they meet the detailed 
solicited AE grading criteria in (Table 10) . 
Updated test:  
The Investigator or appropriately qualified designee 
will review the Diary data online following 
vaccination, to evaluate subject compliance and as part 
of the ongoing safety review. Daily review is optimal 
during the active Diary period. Any solicited symptom 
marked as Grade 3 should be specifically reviewed 
with the subject to ensur e they meet the detailed 
solicited AE grading criteria in (Table 10)  and 
evaluate for potential alternative etiology.  
 
 
  
 
 
 
 
 
 
 
 
Provide  clarification on the post dose 
observation period for the sentinel 
subjects  
 
 
 
 
 
 
 
 
To clarify if ≥ Grade 3 Solicited 
Adverse Events are related to study 
drug or other etiology  
 
 
 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 97 of 106 
 
 7.2 Management 
of Blood / Saliva 
/ Nasal Samples  Added text to be consistent about bio samples 
collection, preparation, storage, and shipment  Provide clarification  
7.2.4  Future 
use of stored 
specimens and 
data Removed the following text:  
In addition to the research, you are consenting to under 
this research study, Vaxart, would like to store your 
samples for future development of a NoV vaccine. At 
this time, the exact tests are not known but this will 
help to further understand the how the  oral NoV 
vaccine works in the body and in the prevention of 
NoV illness. If you agree to permit your samples to be 
analyzed, the results on your particular sample will not 
be provided to you, because it will not be known which 
samples belong to you.  Remov ed subject facing language 
from the protocol.  
8.2 
Immunogenicity 
Assessments  Updated to match the SOA -Immunogenicity 
Assessments and testing.  
Original text:  
Primary Immunogenicity Assessments:  
•Serum:  
oAnti  IgA for both GI.1 and GII.4 by Meso Scale 
Discovery (MSD) assay by dose level -geometric mean 
concentration (GMC) at Day 29 and geometric mean 
fold rise (GMFR) from Day 1 to Day 29.  
Exploratory Immunogenicity Assessments:  
•Serum:  
oAntibody titers for both GI.1 and GII.4 by Histo -blood 
group antigen (HBGA) -Blocking Assay (BT50) - 
geometric mean titer (GMT) and GMFR at Day 29 and 
Day 180  
oAnti - IgG for both GI.1 and GII.4 by MSD assay -
GMC and GMFR at Day 29 and Day 180  
oAnti - IgA for both GI.1 and GII.4 by M SD assay - 
GMC and GMFR at Day 180  Updated to accurately reflect the 
SOA  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 98 of 106 
 
 •PBMC: Anti - IgA Antibody Secreting Cells (ASC) for 
both GI.1 and GII.4 by ELISpot at Day 8  
•Nasal Swab:  
oAnti - IgA for both GI.1 and GII.4 - GMC and GMFI 
at Day 29 and Day 180  
•Saliva:  
oAnti - IgA for both GI.1 and GII.4 - GMC and GMFI 
at Day 29 and Day 180  
•Fixed Whole Blood (required for blood draw, optional 
for testing)  
oB-cell immunophenotyping - Day 8  
Updated text:  
Primary Immunogenicity Assessments:  
•Serum:  
oAnti  IgA for both GI.1 and GII.4 by Meso Scale 
Discovery (MSD) assay by dose level -geometric mean 
concentration (GMC) at Day 8 and Day 29 and 
geometric mean fold rise (GMFR) from Day 1 to Day 8 
to Day 29.  
Exploratory Immunogenicity Assessments:  
•Serum:  
oAntibo dy titers for both GI.1 and GII.4 by Histo -blood 
group antigen (HBGA) -Blocking Assay (BT50) - 
geometric mean titer (GMT) and GMFR at Day 8 and 
Day 29, and Day 180  
oAnti - IgG for both GI.1 and GII.4 by MSD assay -
GMC and GMFR at Day 8, Day 29 and Day 180  
oAnti- IgA for both GI.1 and GII.4 by MSD assay - 
GMC and GMFR at Day 8, Day 29 and Day 180  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL  Page 99 of 106 •Nasal Swab:
oAnti - IgA for both GI.1 and GII.4 - GMC and GMFI 
at Day 1, Day 8, Day 29 and Day 180  
•Saliva:
oAnti - IgA for both GI.1 and GII.4 - GMC and GMFI 
at Day 1 , Day 8, Day 29 and Day 180  
•Fixed Whole Blood (required for blood draw, optional
for testing)
oB-cell immunophenotyping -– Day 1, Day 8, Day 29 
and Day 180  
9.1.1  Definition 
of an Adverse 
Event, Serious  
Adverse Event, 
Adverse Event 
of Special 
Interest, New 
Onset of 
Chronic Illness, 
and 
Unanticipated 
problems  Adver se Event  of Special  Interest  
Original text:  
An adver se event  of special  interest  (seriou s or 
nonserious)  is one of scientifi c and medical  concern  
specific  to the Sponsor’s  product  or program,  for which 
ongoi ng monitori ng and rapid communicati on by the 
Investigator  to the Sponsor  can be appropriate.  
Updated  text: 
Update d text (addition):  
An adver se event  of special  interest  (seriou s or 
nonseriou s) is one of scientifi c and medical  concern  
specific  to the Sponsor’s  product  or program,  for which 
ongoi ng monitori ng and rapid communicati on by the 
Investigator  to the Sponsor  can be appropriate.  For this 
study, an AESI is a serious or non-serious adverse 
events of scientific and medical concern with 
potential immune -mediated medical conditions  as 
well as events associated  with thrombosi s and 
thrombocytopenia  as listed in Table  12. 
Unsolicited  Adverse Events: 
Origina l text:  
If there are no safety  concerns  during  this period 
then randomized Subjects will be kept under Clarify Adverse Event of Special 
Interest (AESI)  
Clarify sentinel post dose 
observation period  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0  09 Feb 2023  
CONFIDENTIAL  Page 100 of 106 observation for 30 minutes after vaccination to 
ensur e their safety.  The post-vaccination 
observation period should be documented 
(including the actual time of observation ) in the 
source document. 
Updated text: 
Sentinel subjects will be kept at the site under 
observation for 2 hours after vaccination to 
ensure their safety.  If there are no safety 
concerns during this period then randomized 
Subjects will be kept under observation  for 30 
minutes  after vaccination to ensure their safety. 
The post-vaccination observation period should be 
documented (including the actual time of 
observation) in the source document.  
9.1.3  
Relationship of 
Adverse Event 
Following 
Immunization to 
Experimental 
Vaccine 
/Vaccine 
Adverse Event 
Causality 
Assessment  Original text:  
For more details refer to 
https://www.who.int/publications/i/item/causality -
assessment -aefi-user-manual -2019.  
Updated text:  
For more details, refer to the causality assessment of an 
adverse event following immunization (aefi): user 
manual for the revised w ho classification second 
edition, 2019 update link 
https://www.who.int/publications/i/item/978924151699
0 Provide updated information  
9.1.5  Time 
Period and 
Frequency for 
Collecting AE, 
AESI, NOCIs, 
and SAE 
Information Original text:  
All AEs AESIs and NOCIs will be collected from the 
first dose of study product until the follow -up visit at 
the timepoints specified in the SoA (Table 1).  Medical 
occurrences that begin before the start of study drug but 
after obtaining informed consent  will be recorded as 
medical history/current medical conditions, not as AEs.  
Updated text:  
Medical occurrences that begin before the start of study 
drug but after obtaining informed consent will be 
recorded as medical history/current medical conditions, 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 101 of 106 
 
 not as AEs if it does n ot have a causal relationship 
with study participation.  There are two situations 
to note as below.  
1. If the medical occurrence causes the subject 
to be excluded from the study, then it must be 
reported by the investigator. This event will then 
need to be  classified as an "AE not related to the 
study drug.”   
2. If the medical occurrence is the result of a 
protocol-specified intervention (prior to study drug 
dose), including but not limited to washout or 
discontinuation of usual therapy, diet, or a 
procedure then these must be reported appropriately as 
an AE (solicited and unsolicited), SAE, AESI, NOCI, 
and other reportable safety events by the Investigator.  
 
 
 
9.1.7  Reporting 
of Adverse 
Event, Adverse 
Event of Special 
Interest, New 
Onset of 
Chronic Illness, 
Serious Adverse 
Events and 
Unanticipated 
problems  Original text:  
All AEs (solicited and unsolicited), AESIs, NOCIs 
SAEs and other reportable safety events that  occur after 
the consent form is signed but before study product 
administration must be reported by  the Investigator if 
the event cause the subject to be excluded from the 
study or is the result of a  protocol -specified 
intervention, including but not limited to washout or 
discontinuation of usual  therapy, diet, or a procedure.  
Updated  text: 
All AEs (solicited and unsolicited), AESIs, NOCIs 
SAEs and other reportable safety events that occur after 
the consent form is signed but before study product 
administration must be reported by the Investigator if 
the event cause the subject to be e xcluded from the 
study (these will be reported as “AE not related to 
the study drug”)  or is the result of a protocol -specified 
intervention, including but not limited to washout or 
discontinuation of usual therapy, diet, or a procedure.  Provide clarificati on on reporting of 
AEs 
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 102 of 106 
 
 10.2 Safety 
Monitoring 
Committee  Original text:  
The first 10 randomized subjects will receive open 
label high dose of active vaccine (2×1011). After Day 8 
is completed for the 10 sentinel subjects, enrollment 
will be paused for a safety review  of Solicited 
Symptoms and unsolicited adverse events. If no dose -
related toxicities are observed,  and upon consideration 
of the SMC recommendations following review of 
safety data, enrollment  of the remaining subjects will 
be initiated.  
Updat ed text:  
The first 10 sentinel  subjects will receive open label 
high dose of active vaccine (2×1011) in a staggered 
manner, no more than two (2) subjects dosed in a 
24-hour period. All subjects dosed will be observed 
for a minimum of 2 hours post dose. While ten (10) 
subjects will be dosed in the sentinel group, to allow 
for dropouts, eight (8) subjects w ith complete safety 
data (defined as Day 1 to Day 8) will be enough to 
convene the SMC.  If no dose -related toxicities are 
observed, and upon consideration of the SMC 
recommendations following review of safety data, 
enrollment of the randomized double -blind  study will 
be initiated.   Provide clarification on the open 
label -sentinel dosing portion of the 
study  
11.1 Hypothesis  Original text:  
The following hypotheses will be tested using MSD 
IgA fold rise as the endpoint of interest.  
Null Hypothesis: H0: P1 - P2 ≤ 0.  
Alternative Hypothesis: Ha: P1 – P2 > 0.  
Where p1 is the percentage of MSD IgA fold rise for 
the low dose level and P2 for the high dose  level.  
All statistical tests will be performed at the 7% level of 
significance and confide nce intervals will  also be 
presented.  
Updated text:  
No hypothesis testing is planned for this study.  There will be no hypothesis testing 
for this study  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 103 of 106 
 
 11.2 Sample 
Size 
Determination  Original text:  
A sample size of 613 randomized subjects (245 each in 
medium and high dose levels and 123 in  placebo) are 
required to achieve 80% power, at the 7% significance 
level (one -sided) using a 2 -group fisher exact test with 
equal allocation to each dose level. Calculation 
assumes a difference  of 10.2% in MSD IgA fold rise 
between the two dose groups (72.7 % Vs. 62.5%). 
Placebo was  added for safety comparison. The numbers 
of subjects per dose group are predicted to yield  
meaningful safety and immunogenicity results.  
Updated text:  
A sample size of 125 randomized subjects (50 each in 
medium and high dose levels and 25 in placebo) in 
addition to 10 sentinel subjects are not based on formal 
statistical testing but rather based on clinica l judgement 
and predicted to yield meaningful safety and 
immunogenicity results. Placebo was added for safety 
comparison.  
 Modification based on clinical 
judgement   
11.5.2  Analysis 
of the Primary 
Safety End 
Points  Original text:  
Primary -(measured from  Day 1 through  Day 365)  
requency, duration, and severity of Solicited Symptoms 
of Reactogenicity (local, systemic)  measured daily for 
1 week following vaccination.  
Frequency, duration, and severity of unsolicited AEs, 
and SAEs through the active period (4  weeks post last 
dose).  
Frequency, duration, and severity of SAEs, AESIs 
and NOCIs for 1 year following the study drug dose.  
Descriptive statistics will be provided for each 
reactogenicity endpoint for each dose. Local  reactions 
and systemic events from Day 1 through Day 8 after 
each dose will be presented by   
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 104 of 106 
 
 Removed: Frequency, duration, and severity of 
SAEs, AESIs and NOCIs for 1 year following the 
study drug dose.  
Added a new endpoint:   
Exploratory (measured from Day 30 through Day 365)  
Frequency, duration, and severity of SAEs, AESIs and 
NOCIs for 1 year following the study drug dose.  
11.5.3  Analysis 
of Primary 
Immunogenicity 
End Points  Original text:  
11.5.3  Analysis of Primary End Points  
Updated text:  
11.5.3  Analysis of Primary and Exploratory 
Immunogenicity End Points  
Original Text -Primary: 
All measures will be analyzed comparing the two 
active vaccine groups. The immunogenicity set will be 
used for this analysis. All results will be presented 
descriptively and summarized by treatme nt groups.  
Anti- IgA for both GI.1 and GII.4 by Meso Scale 
Discovery will be summarized descriptively.  
Updated text:  
All measures will be analyzed comparing the two 
active vaccine groups. The immunogenicity set will be 
used for this analysis. All results will be presented 
descriptively and summarized by treatment groups.  
For specific primary immunogenicity endpoints 
please refer to Section 8.2 -Immunogenicity 
Assessments - Primary Immunogenicity 
Assessments:  
Original text  Exploratory : 
none  Clarified Primary 
Immunogenicity and added 
Exploratory Immunogenicity  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 105 of 106 
 
 Updated text:  
All measures will be analyzed comparing the two 
active vaccine groups. The immunogenicity set will be 
used for this analysis. All results will be presented 
descriptively and summarized by treatment groups. The 
analysis of these bio samples is optional.  
For specific exploratory immunogenicity endpoints 
please refer to Section 8.2 -Immunogenicity 
Assessments - Exploratory I mmunogenicity 
Assessments  
14.1 Early 
Safety Data 
Review 
AND/OR 
Committee  Original text:  
An initial safety review for this study is planned for the 
first 10 sentinel subjects who will receive  the high dose 
and provide safety data after administration of 2×1011 
dose level. All safety data  collected will be summarized 
and reviewed by the (Sponsor’s internal/external safety 
monitoring  committee) for agreement of next steps.  
Updated te xt: 
An initial safety review for this study is planned for the 
first 10 sentinel subjects who will receive the high dose 
and provide safety data after administration of 2×1011 
dose level in a staggered manner, no more than two 
(2) subjects dosed in a 24 -hour period. All subjects 
dosed will be observed for a minimum of 2 hours 
post dose . All safety data collected will be summarized 
and reviewed by the (Sponsor’s internal/external safety 
monitoring committee) for agreement of next steps.  
 The original version of the protocol 
allowed for enrollment of the 10 
sentinel subjects without limitations. 
This amendment limits sentinel 
dosing to 2 subjects per 24-hour 
period and extends the sentinel 
observation period to 2 hours post 
dose.  This modif ication was 
originally captured in a protocol 
clarification letter (PCL#3) and the 
ICF modified prior to this 
amendment.  
Appendix 6.0  Original  text: 
Updated text:  Capture protocol version history and 
provide a table of protocol changes 
and rationale  
DocuSign Envelope ID: 

Vaxart Inc  
VXA -NVV -202 Version 2 .0                     09 Feb 2023  
CONFIDENTIAL                                                                                                                                                       Page 106 of 106 
 
  
 
 
 
 
 
 
 
 
  
DocuSign Envelope ID: 
